Author: Dr Shroom

Last updated: April 2026 · For adults 19+ in Canada · Informational only · Not medical or legal advice

DMT Vape vs Raw DMT in a Bong: What Is Different, What Is Riskier, and What People Should Know

Medical and legal disclaimer: This article is for education and harm reduction only. It is not medical advice, legal advice, or a recommendation to use any illegal substance. DMT is controlled in many places, including Canada outside specific exemptions. Do not drive, work, or make high-risk decisions while impaired.

Quick summary: A DMT vape and raw DMT in a bong can both produce very intense effects, but they differ in consistency, heat control, respiratory stress, and how quickly intensity can escalate. A vape is often described as more repeatable and easier to titrate. A bong setup is often described as harsher, less predictable, and easier to over- or under-heat. Neither method is risk-free.

If you are researching DMT methods, the most useful question is not “which is stronger?” It is “which setup introduces fewer unknowns and fewer avoidable harms?” This guide compares the two in plain language and explains where people get into trouble.

For baseline context, see Shroom Bros on DMT: Everything You Need to Know, How DMT Vapes Work, and DMT Vapes and Cartridges.

First: What we are comparing

This article compares:

• DMT vape (pre-mixed liquid in a cartridge with a battery)
• Raw/freebase DMT in a bong-style setup (solid material vaporized using a manual heat source)

Both routes are inhaled and both can become overwhelming very fast. The differences are mostly about control, consistency, and side effects from poor heat handling.

Big difference #1: Heat control and chemical stability

DMT needs to be vaporized in a useful temperature window. Too cool and effects can feel weak. Too hot and material can burn or degrade, creating a harsh inhale and wasted product.

With many vapes, heat is more stable because the battery and coil are built for repeatable output. With bong-style manual heating, heat can swing a lot from one attempt to the next, depending on flame distance, timing, airflow, and user technique.

Plain English: a vape often gives more repeatable vapor conditions; manual bong heating often has more room for error.

Big difference #2: Dose consistency and escalation speed

People often report that vapes allow smaller, more gradual inhalations with less setup friction. That can feel easier to pace. But because the process is easy, people may take repeated pulls quickly and accidentally escalate intensity.

With raw DMT in a bong-style setup, each attempt can vary more. That variability can produce either weak attempts or sudden heavy effects when conditions line up. Inconsistent delivery is one reason people describe this route as less predictable.

Takeaway: “easier to use” does not mean “low risk.” It often means intensity can build before a person notices how far they have gone.

Big difference #3: Lung and throat irritation

Respiratory irritation is a common complaint. Harsher vapor is more likely when material overheats or burns. In real-world reports, manual high-heat setups are more often linked with burning sensation, coughing, chest discomfort, and unpleasant taste.

Cartridge vapor is not harmless, but many users describe it as smoother and less physically punishing than poorly heated raw setups. Device quality, liquid formulation, and contamination still matter.

Important: if someone already has asthma, bronchitis, COPD, or other lung issues, inhaled psychoactives can raise risk.

Big difference #4: Practical safety around impairment

DMT effects can begin very fast. A person may lose motor control, awareness of surroundings, or ability to communicate within seconds to minutes. That creates immediate physical safety risks (falls, burns, dropping hot objects, panic movement).

Manual bong-style heating introduces extra hazards before and during onset: open flame, hot glass, and more complex handling. A vape may remove open flame risk, but it does not remove impairment risk.

• Manual heat route: more burn and handling hazards.
• Vape route: fewer flame hazards, but still very high impairment risk.

Big difference #5: Reliability of what is actually in the product

Raw crystal and cartridges both carry quality uncertainty in unregulated markets. With cartridges, people cannot easily verify concentration, cutting agents, or contamination without proper lab testing. With raw material, purity and identity can still be uncertain.

This is one of the biggest blind spots in all online method debates. People compare “device A vs device B” while ignoring that unknown chemistry can dominate the outcome.

What users usually mean by “vape is easier”

When people say vapes are easier, they usually mean:

Less setup complexity

• Less heat guesswork
• Fewer failed attempts from overheating
• Less harsh throat hit (for many users)

That does not mean the psychological experience is easy. DMT can still be disorienting, intense, and emotionally destabilizing regardless of device type.

What users usually mean by “raw in a bong hits harder”

Some people say bong-style delivery feels “harder” or more abrupt. In many cases, that impression is a mix of:

• Sudden delivery when technique happens to line up
• Harshness and cough being interpreted as intensity
• Large variation between attempts (one weak, next very strong)

So “harder” does not always mean “better delivery.” Sometimes it means more chaotic delivery.

Mental health risks do not disappear with any device

No device removes core psychedelic mental risks. People with personal or family history of psychosis, bipolar mania, severe panic disorder, or unstable mood may face higher risk from very intense experiences.

Even in people without diagnosed conditions, short intense states can trigger panic, derealization, confusion, and distress afterward. Device choice changes logistics – not fundamental neuropsychological risk.

Related reading: What Are the Risks of Psychedelics?

Medication and substance mixing concerns

Mixing psychoactives raises unpredictability. Combining with alcohol, cannabis, stimulants, or multiple serotonergic drugs can amplify confusion and physical stress. If someone is on psychiatric medication, interaction risk should be discussed with a clinician, not guessed from forums.

For antidepressant interaction context, see your internal guide on SSRIs/SNRIs and psilocybin. The broader point still applies here: mixed-substance states are harder to predict and manage.

Harm-reduction baseline (non-technical)

This is not a how-to section. It is a risk-minimization baseline:

• Do not use alone.
• Do not combine with driving, tools, heights, water, or fire.
• Avoid stacking substances.
• If someone has chest pain, severe confusion, breathing trouble, or dangerous behavior, seek emergency help.

Safer planning is always less dramatic and less impulsive than internet highlight clips.

Simple comparison table (plain language)

• Consistency: Vape usually more repeatable; manual bong route more variable.
• Heat control: Vape usually easier; manual route easier to overheat.
• Harshness: Manual route often harsher if heat is off.
• Physical setup risk: Manual route adds open-flame/hot-glass hazards.
• Mental intensity risk: High for both; neither is psychologically “safe.”
• Unknown product risk: Present in both when unregulated.

FAQ

Is a DMT vape safer than raw DMT in a bong?

It may reduce some mechanical risks (open flame, rough heat swings), but it does not remove core impairment or mental health risks. “Safer” is relative, not absolute.

Why do people say the bong method is harsher?

Mostly heat control issues. Overheating can produce a rough inhale and cough, which many people describe as harsh or unpleasant.

Which one is stronger?

Strength depends on many factors: concentration, heat, inhalation pattern, individual sensitivity, and product quality. Device type alone does not determine outcome.

Can I trust forum dosing claims?

Not as medical or safety guidance. Forum reports are anecdotal and often leave out key details.

Where can I learn more on your site?

Start with DMT: Everything You Need to Know, How DMT Vapes Work, and DMT Vapes and Cartridges.

The bottom line

DMT vape vs raw DMT in a bong is mostly a question of consistency and avoidable hazards, not a question of one route being harmless. Vapes are often seen as easier and more repeatable. Manual bong setups are often seen as harsher and more variable. Both can become overwhelming quickly, and both carry legal, physical, and mental health risks.

If your goal is informed decision-making, prioritize verified information, conservative planning, and safety over intensity chasing.

Explore more educational articles on the Shroom Bros blog

Sources and references

1. Shroom Bros: DMT – Everything You Need To Know In 2024
2. Shroom Bros: How DMT Vapes Work
3. Shroom Bros: DMT Vapes and Cartridges
4. Shroom Bros: What Are the Risks of Psychedelics?
5. Government of Canada: Controlled and illegal drugs

Disclaimer: Educational content only. Not medical or legal advice. If you have health concerns, speak with a licensed professional.

Most people know LSD as the drug that makes you see things. Fractals. Trails. Colours bleeding into one another. The walls breathing.

But that description — while not wrong — barely scratches the surface of what’s actually happening inside your skull when lysergic acid diethylamide enters your bloodstream and begins its long, strange, systematically documented takeover of your brain’s most fundamental functions.

This post is not about whether you should take LSD. It’s about what happens when you do — at a neurological level, hour by hour, from the moment a tab dissolves under your tongue to the lingering glow that remains the following morning.

Because what LSD does to the human brain is, from a purely scientific perspective, one of the most extraordinary pharmacological events we have ever documented. And the science behind it — from Imperial College London’s landmark neuroimaging studies to the latest 2025 research on brain network restructuring — tells a story that is far more nuanced, and far more fascinating, than anything the pop-culture version of acid ever suggested.

Let’s break it down.

First: Why Does LSD Do Anything At All?

Before the timeline, a critical foundation: why is LSD so powerful, and why does it last so absurdly long?

LSD — lysergic acid diethylamide — was first synthesized in 1938 by Swiss chemist Albert Hofmann, who discovered its psychedelic effects accidentally five years later after absorbing a small amount through his fingertips. It remains one of the most potent psychoactive substances ever discovered. A typical recreational dose is measured in micrograms — millionths of a gram — yet produces an experience that can last 8 to 12 hours and alter the trajectory of a person’s life.

The mechanism begins with receptor binding. LSD is a non-selective serotonin receptor agonist — it binds to most serotonin receptor subtypes in the brain, with its primary psychedelic effects mediated through the 5-HT2A receptor. These receptors are concentrated in the prefrontal cortex, the thalamus, and several other higher-order cortical regions. When LSD activates them, it triggers a cascade of neural events that fundamentally reorganises how the brain processes information.

But here’s the key to understanding why LSD lasts so long: when an LSD molecule lands on a 5-HT2A serotonin receptor, the receptor physically folds over the molecule and locks it in place — like a trapdoor closing. The drug’s effects will not begin to fade until the molecules are knocked off or come loose from the receptor. This can take anywhere from 6 to 15 hours. The brain essentially traps its own disruptor inside its own machinery, and cannot stop the experience until the molecule works its way free on its own terms.

Additionally, LSD has recently been found to act as a highly potent positive allosteric modulator of TrkB — the receptor for Brain-Derived Neurotrophic Factor (BDNF) — which explains why even a single LSD experience can produce measurable neuroplastic changes that persist for weeks or months after the molecule itself is completely gone.

Neuroimaging studies, most importantly the landmark 2016 work from Imperial College London’s Centre for Psychedelic Research, confirm that LSD reduces the efficacy of thalamo-cortical information filtering, decreases oscillatory power within the default mode network, and fundamentally flattens the hierarchical organisation of large-scale brain activity. What this means in experiential terms unfolds over the following hours.

The Hour-by-Hour Brain Breakdown

Note: The timeline below is based on a standard oral dose of approximately 100–150 micrograms of LSD, taken on an empty stomach. Individual experiences vary based on dose, body weight, metabolism, emotional state, and environment.

⏱ Minutes 0–30: Ingestion and the Invisible Beginning

The tab goes under the tongue. The clock starts. And for the first twenty to thirty minutes: nothing you can consciously detect.

But things are already moving. LSD is being absorbed through the sublingual mucosa into the bloodstream. It passes through your stomach and small intestine, enters the bloodstream, and is carried through the body and into the brain. Your liver begins metabolising it using the CYP2D6 enzyme — but this process is slow, and most of the active compound reaches the brain intact.

Pharmacokinetic data from a landmark 2017 clinical study at the University of Basel found that in healthy subjects given a 200 microgram oral dose, mean maximal LSD plasma concentrations were reached at a median of 1.5 hours post-administration — but the compound begins crossing the blood-brain barrier and binding to receptors well before plasma levels peak. The average duration of subjective effects ranges from 6.7 hours at the lowest doses to 11 hours at higher doses.

At this moment in the timeline, your neurons are beginning their encounter with LSD molecules for the first time. 5-HT2A receptors in the prefrontal cortex begin to activate. The thalamus — the brain’s gatekeeper and sensory relay station — begins receiving altered signals. Nothing is visible yet. But the machinery is turning.

What you feel: A quiet awareness that something is different. Perhaps a faint electric quality to the air. A subtle luminosity to colours. A restlessness or excitement that is hard to source. Some people feel mild nausea or stomach awareness during this window, particularly on a full stomach.

What your brain is doing: LSD molecules are landing on 5-HT2A receptors and being locked in place. The prefrontal cortex is beginning to receive dramatically altered serotonergic input. The thalamic gating mechanism — which normally filters the overwhelming torrent of raw sensory data before it reaches conscious awareness — is beginning to loosen.

⏱ Hour 1: The Come-Up — Reality Softens

This is when you know. Unambiguously, undeniably, irreversibly: you know.

The come-up of LSD is distinct — and for many people, it is one of the most electrically charged hours of the entire experience. The world begins to reorganise. Colors become saturated in a way that seems impossible — not brighter exactly, but more present, as if the visual filter you’ve always lived behind has been partially removed. Surfaces begin to breathe. Objects acquire subtle movement and texture they didn’t have before.

The thalamic filter is failing. Under normal circumstances, the thalamus — acting as the brain’s “information gatekeeper” — filters the massive raw stream of sensory data flowing in from your eyes, ears, skin, and internal organs, and passes only what it deems relevant to conscious awareness. LSD disrupts this filtering. Suddenly, more of everything gets through. The world doesn’t look different because your eyes are seeing differently — it looks different because your brain is letting you see more of what was always there.

At the neurological level, the serotonin 5-HT2A receptors in the visual cortex are now significantly activated. Research from Imperial College London’s landmark 2016 neuroimaging study, published in the Proceedings of the National Academy of Sciences, showed that increased visual cortex cerebral blood flow and dramatically expanded primary visual cortex (V1) functional connectivity correlated strongly with ratings of visual hallucinations — implying that intrinsic brain activity exerts greater influence on visual processing in the psychedelic state. The visual system is no longer passively receiving the outside world. It has become an active generator of experience.

Emotional effects intensify. LSD can amplify your mood significantly. If you’re in a positive, safe environment when the come-up hits, you may feel waves of warmth, joy, and profound gratitude for existence. The emotional tone of the come-up is one of the strongest predictors of the trip’s overall character — which is why “set and setting” (your mental state and environment) matters so profoundly at this moment. If anxiety or fear is present, this hour can feel destabilising.

Time begins to distort. Nearly all people who take LSD report that it alters their perception of time. During the come-up, time typically slows and thickens — what feels like an hour may be twenty minutes. Your relationship to clock time begins its long departure.

Physical effects emerge: Pupil dilation (one of LSD’s most reliable physical signatures). Slight elevation in blood pressure and heart rate. Mild jaw tension. A tingling or electric sensation across the skin. Body temperature fluctuation — waves of warmth followed by subtle chills. These are largely the result of LSD’s secondary activity at adrenergic receptors, producing a mild sympathomimetic response.

What to do: This is the moment to be where you want to be. Find a safe, comfortable space. Don’t fight the come-up — it cannot be stopped, and resistance amplifies anxiety. Breathe slowly. Trust that what is coming is temporary.

⏱ Hours 2–3: The Brain’s Normal Organisation Dissolves

By the second hour, LSD is doing something that no other pharmacological event in ordinary life produces. It is dismantling the default architecture of your brain.

Under normal circumstances, the brain operates through segregated, specialised networks. The visual network handles vision. The auditory network handles sound. The default mode network manages self-referential thought, memory, and the sense of being a distinct “you.” These networks operate relatively independently — each doing its job without excessive cross-communication.

LSD terminates this arrangement.

Research published in Current Biology from Imperial College London, titled Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution, demonstrated that LSD dramatically increases global functional connectivity across the brain — networks that normally operate independently begin communicating with each other extensively. The visual network starts receiving input from the auditory network. The emotional processing regions begin feeding into sensory cortex. The default mode network loses its coherence and its grip on the self.

And from a Nature Communications study using network control theory and fMRI data: LSD and psilocybin flatten the brain’s control energy landscape, reducing the energetic cost of transitioning between brain states. Where the normal brain follows constrained neural highways — predictable paths from state to state — the LSD brain becomes a landscape where those highways have dissolved and every direction is equally navigable. Brain state transitions become fluid, effortless, and radically unpredictable.

Synesthesia begins. When network segregation breaks down, the senses begin bleeding into each other. Music becomes visual — you may see sounds as colours, shapes, or spatial forms. Textures may have tastes. Light may have sound. This is real synesthesia — not metaphor — produced by the literal cross-activation of sensory cortices that do not normally communicate. It is one of LSD’s most reliably reported and scientifically documented phenomena.

Thought patterns accelerate and liquefy. Ideas connect to other ideas with unusual speed and emotional resonance. Conceptual leaps that would ordinarily require deliberate analytical effort happen spontaneously and feel profoundly meaningful. This is the “entropic brain” — the term coined by neuroscientist Robin Carhart-Harris to describe the state of increased neural entropy produced by psychedelics, in which the brain’s spontaneous activity becomes more complex, more diverse, and less constrained by its usual hierarchical order.

The ego begins to loosen. The default mode network — the brain’s self-referential hub, responsible for your internal narrative, your sense of being a distinct person separate from the world — is losing its coherent grip. You may begin to notice that the internal voice that usually narrates your experience is quieting. This is the beginning of what will deepen, at higher doses, into full ego dissolution.

⏱ Hours 3–5: The Peak — The Brain Rebuilt From Scratch

The peak of an LSD trip at a standard dose typically occurs between 2 and 4 hours after ingestion, with the most intense effects lasting through the fifth hour. This is the deepest territory of the experience, and the most scientifically documented.

Here is what is concurrently happening in the brain during the LSD peak:

The visual cortex is generating reality, not receiving it. Imperial College’s neuroimaging research showed that under LSD with eyes closed, many more areas of the brain than normal contribute to visual experience. The closed-eye visuals of LSD — geometric mandalas, fractal architectures, landscapes of impossible colour and depth — are not random static. They are the brain’s own imagery, generated internally, now amplified and projected with the same perceptual conviction as ordinary reality. As Dr. Robin Carhart-Harris described: “We observed brain changes under LSD that suggested our volunteers were ‘seeing with their eyes shut’ — albeit they were seeing things from their imagination rather than from the outside world.”

Ego dissolution reaches its fullest expression. At peak, the default mode network has lost its normal dominance. Research from Imperial College London published in PNAS showed that decreased connectivity between the parahippocampus and retrosplenial cortex correlated strongly with ratings of “ego dissolution” and “altered meaning” — implying the importance of this particular circuit for the maintenance of “self” and its processing of “meaning.” When this circuit loses coherence, the subjective experience is a dissolution of the boundary between self and world. The internal narrator quiets or disappears. There is awareness, but it is no longer owned by anyone. Many people describe this as one of the most profound experiences of their lives. It is also, for some people, the most frightening.

A 2025 study from King’s College London and Imperial College London, published in Human Brain Mapping, specifically identified the dorsolateral prefrontal cortex (DLPFC) and its connection to the thalamus as critical nodes in the “ego dissolution network” — finding that LSD increased information flow between these regions in the theta band, substantiating the hypothesis that disruptions in thalamic gating underlie the experience of ego dissolution. The thalamus — which normally acts as the gatekeeper between raw experience and conscious awareness — has become permeable, allowing what was previously filtered to flood into consciousness.

Emotional intensity reaches its maximum. The peak of LSD amplifies whatever emotional material exists in the psyche at that moment. Joy becomes ecstasy. Wonder becomes awe. Fear becomes terror. Love becomes a cosmic force. The limbic system — the brain’s emotional processing hub — is receiving maximally disrupted input from a prefrontal cortex that can no longer apply its usual regulatory brakes. Emotional material that normally sits beneath the surface of awareness can emerge with startling power and clarity.

The REBUS model — what this all means. The dominant scientific model for how LSD and other psychedelics alter consciousness is the REBUS model — Relaxed Beliefs Under Psychedelics — developed by Carhart-Harris and colleagues. It proposes that psychedelics alter conscious experience by relaxing the brain’s top-down “prior beliefs” about how the world should be perceived, and allowing bottom-up sensory information to exert greater influence on experience. The predictive processing machine that normally constructs a stable, reliable, consensus reality from raw sensory data has been partially disabled. What replaces it is an experience built more directly from raw perception — which is simultaneously more vivid, more meaningful, more emotionally resonant, and far less predictable.

Time has stopped making sense. At peak, objective clock time becomes genuinely irrelevant. Many users report that peak states felt like hours when only minutes passed, or that entire lifetimes seemed to be experienced in a single moment. This is not subjective impression — it reflects real changes in the brain’s temporal processing. The normal rhythmic oscillations that help the brain track time have been disrupted by LSD’s action on multiple receptor systems.

⏱ Hours 5–7: The Plateau — Integration Begins

After the peak, the intensity begins to soften — but only gradually, and not linearly. LSD’s plateau phase is long: the effects remain significantly active for two to three hours after the peak, gradually declining in intensity while remaining qualitatively similar in character.

Visual phenomena remain present but become more gentle. Open-eye visuals — the breathing of surfaces, the movement of patterns, the unusual saturation of colour — continue but are less overwhelming. Closed-eye visuals soften from architectural complexity to flowing imagery. The sense of ego dissolution typically relaxes into something more like profound openness or expanded awareness — still distinctly psychedelic, but no longer boundless.

Cognitively, the plateau is often where the most meaningful personal material surfaces. With the peak’s overwhelming intensity behind you, the mind begins to process what it has encountered. Insights — about your life, your relationships, your patterns, your fears, your purpose — arise with unusual clarity and felt certainty. These insights are not random. They reflect the brain’s enhanced connectivity and reduced self-referential defensiveness, which together create conditions in which emotional and psychological material can be seen without the usual distortions of ego-protection.

Music takes on particular significance during this phase. Research from the Beckley/Imperial Research Programme found that listening to music while on LSD triggered significant changes in how the brain processes and integrates auditory information — with emotional responses to music substantially amplified, and the subjective meaning of musical pieces dramatically enhanced. Many people describe specific pieces of music heard during an LSD plateau as among the most moving and meaningful musical experiences of their lives.

Physically, the body is still in sympathomimetic activation — elevated heart rate, pupil dilation, muscle tension. Fatigue begins to accumulate beneath the experience, as the nervous system has been running at elevated capacity for hours. Staying hydrated and warm is important during this window.

⏱ Hours 7–9: The Descent — Reality Re-Assembles

The brain’s default networks begin to reassert themselves. The 5-HT2A receptors, still occupied by LSD molecules, are beginning to release them gradually as the molecules come loose from their receptor pockets under the body’s metabolic pressure.

Visual distortions continue to fade. Open-eye movement and colour saturation diminish. The internal narrative — the self, the ego, the “I” — gradually returns. This return is often accompanied by a profound sense of relief and, simultaneously, a particular kind of wistfulness — the recognition that something enormous is receding.

After the peak of an LSD trip, the comedown signals the gradual return to normal consciousness, with LSD’s effects slowly fading. Hallucinations start fading, but thoughts may remain abstract and introspective. Some experience mental and physical exhaustion from the intensity of the peak phase, while many describe the late descent as peaceful, with a sense of profound clarity and emotional settledness.

Cognitively, this is a valuable window. The brain remains more plastic and less defensively organised than in ordinary waking life, but is no longer overwhelmed. Insights from earlier in the experience can be examined, turned over, and articulated — often for the first time. This is an excellent time to write, if you have the energy and focus.

Some people experience mild anxiety during the descent — a sense of returning to ordinary reality that feels, after the expanse of the peak, somewhat constraining. This is normal and passes. The brain is literally rebuilding the structures of ordinary consciousness, and the process isn’t always seamless.

⏱ Hours 9–12: The Comedown — Reintegration

By this stage, most of the drug’s acute psychedelic effects have subsided. The visual field has returned to normal. The ego is back. Time flows normally again. The trip is over in its most dramatic sense — but the experience is not finished.

What remains in the comedown is a particular quality of consciousness that is hard to describe to anyone who hasn’t experienced it: a profound emotional tenderness, a heightened perceptual sensitivity, and a feeling of having travelled somewhere enormous and returned changed. Simple things — a glass of water, a conversation with a friend, the texture of a blanket — can feel unusually meaningful and present.

Physically, the body is tired. The sympathomimetic activation of the past several hours has been energetically costly, and fatigue now asserts itself clearly. Muscle tension, mild headache, jaw soreness, and physical heaviness are common. This is not toxicity — it’s the ordinary exhaustion of a nervous system that has been running at extraordinary intensity for most of a day.

Sleep is typically difficult during the comedown phase. Even when the acute effects have faded, the brain remains subtly activated — more associative, less prone to the settled, downregulated state that supports sleep. Most people find they cannot sleep until 10 to 14 hours after ingestion, even if the trip itself ended earlier.

Emotionally, the comedown is highly variable. Many people feel a deep, settled peace — a sense of having processed something significant and having arrived somewhere new. Some feel fragile and tender, which is equally valid. Some feel mild flat affect or low mood as the dopamine and serotonin systems recalibrate to baseline. All of these responses are normal and temporary.

⏱ Hours 12–24: The Afterglow — Something Remains

The afterglow of LSD is real, documented, and one of the most therapeutically significant aspects of the experience.

After your trip is over, you may experience “afterglow” effects for another six hours — lingering effects of happiness, emotional openness, or a feeling of “lightness” in life. Between the initial trip and the comedown, it can take up to 24 hours for your body and brain to return fully to their typical state.

The afterglow is characterised by heightened emotional sensitivity, enhanced perspective, unusual clarity about what matters in life, and a sense of connection to others and to the world that carries a particular quality of realness and intimacy. It is not a residue of the psychedelic state — it is the brain’s newly reorganised neural architecture experiencing the ordinary world through eyes that have been fundamentally changed.

Research published in Psychopharmacology on long-lasting subjective effects of LSD in healthy subjects found that after a single 200 microgram dose, positive attitudes about life and self, positive mood changes, altruistic and positive social effects, and positive behavioral changes were all significantly elevated — not just immediately after, but at 1 month and 12 months follow-up. After 12 months, 10 of 14 participants rated their LSD experience as among the top 10 most meaningful experiences of their entire lives.

The afterglow is also when the most important integration work begins. The neurological “writing window” is open — the brain is in a state of heightened plasticity, and what you think, feel, and reflect on during this period will shape what new patterns consolidate. Journaling, reflective conversation, time in nature, and gentle creative work are all excellent uses of the afterglow.

What LSD Does to the Brain: A Neuroscience Summary

1. The 5-HT2A Receptor Is the Master Switch

All of LSD’s primary psychedelic effects — the visual hallucinations, the ego dissolution, the enhanced emotional intensity, the time distortion — are mediated through the 5-HT2A serotonin receptor. Research from multiple institutions has confirmed that blocking this receptor with ketanserin (a 5-HT2A antagonist) completely prevents the psychedelic response to LSD, even at high doses. The 5-HT2A receptor is most densely expressed in the higher-order cortical regions responsible for self-referential thought, sensory integration, and executive function — exactly the regions that LSD’s experience most profoundly disrupts.

2. The Default Mode Network Goes Offline

The Default Mode Network (DMN) — the brain system responsible for self-referential thought, internal narrative, and the sense of being a distinct “self” — is significantly suppressed by LSD. Neuroimaging studies consistently show decreased DMN connectivity and oscillatory power under LSD, which correlates directly with the subjective experience of ego dissolution. When the DMN loses its grip, the experience of being a bounded, separate self dissolves — and what remains is awareness without a defined centre.

3. Global Brain Connectivity Explodes

LSD dramatically increases global functional connectivity — the degree to which distinct brain networks communicate with each other. Under normal conditions, brain networks are segregated: each does its own job. Under LSD, this segregation breaks down and a state of massively increased global communication emerges. This is what produces synesthesia, the sense of universal connection, the perception that everything is deeply interrelated, and the dreamlike quality of LSD’s visual and conceptual content.

4. The Brain’s Energy Landscape Flattens

Research using network control theory published in Nature Communications demonstrated that LSD flattens the brain’s “control energy landscape” — reducing the energetic cost required to transition between brain states. Under normal conditions, the brain follows well-worn neural pathways, transitioning between states with specific energetic requirements. LSD makes all state transitions equally easy, producing an experience of radical psychological fluidity — the mind moves freely between emotional registers, conceptual frameworks, and perceptual modes without the usual friction of ordinary consciousness.

5. Neuroplasticity Is Promoted

LSD, like other psychedelic compounds, has been found to increase the expression of genes related to synaptic plasticity — what researchers call “psychoplastogenic effects.” This appears to be mediated by serotonin 5-HT2A receptor agonism and by LSD’s action as a potent positive allosteric modulator of TrkB, the BDNF receptor. Research from Ly et al. (2018) showed that LSD, DMT, and related compounds significantly increase the complexity of dendritic arbours and promote neuritogenesis and spinogenesis — the physical growth of new neural connections. The experience of LSD is not just a pharmacological event. It is a neuroplastic one.

LSD vs Psilocybin: The Key Differences

The most common question people have about LSD is how it compares to magic mushrooms. Both are serotonergic psychedelics acting primarily at 5-HT2A receptors, and both produce broadly similar neurological effects — ego dissolution, increased global connectivity, suppressed DMN activity. But there are important differences worth understanding:

• Duration: LSD lasts significantly longer — typically 8–12 hours vs. 4–6 hours for psilocybin. This makes LSD a more demanding commitment in both preparation and integration.
• Character: LSD is generally described as more stimulating, more visually precise, and more cognitively activating. Psilocybin tends to feel warmer, more emotional, and more inwardly directed. This is likely due to LSD’s additional activity at dopaminergic and adrenergic receptors, which psilocybin lacks.
• Dose control: Psilocybin mushrooms offer more transparent dosing — you can measure grams of dried mushroom with reasonable predictability. LSD doses on blotter paper are impossible to verify without chemical testing, which adds significant harm-reduction complexity.
• Onset: LSD has a longer, more gradual come-up than psilocybin — which can feel more abrupt and wave-like in its onset.

For a full comparison, read our LSD vs Magic Mushrooms guide.

The Therapeutic Picture

LSD is not just being studied as a curiosity. It is being actively investigated as a treatment for some of the most treatment-resistant conditions in modern psychiatry.

LSD is currently being explored in conjunction with psychological support as a treatment for generalized anxiety disorder and depression, with research ongoing at Imperial College London and other institutions. A 2025 study from King’s College London specifically investigated LSD’s role in ego dissolution as it relates to depression — noting that hypofunction in the left dorsolateral prefrontal cortex is associated with depression, and that LSD’s action on this region may be one mechanism of its antidepressant potential.

The clinical picture at this stage is promising but early. What is established is that a single high-dose LSD experience, when properly supported, can produce lasting positive changes in personality, mood, and life satisfaction that persist for twelve months or longer. That’s not a drug effect — that’s a transformation.

Harm Reduction: What You Need to Know

✅ Essential Prerequisites

• No personal or family history of psychosis, schizophrenia, or bipolar disorder
• Not currently on SSRIs, MAOIs, or lithium — these can interact unpredictably and dangerously with LSD
• A trusted, sober companion present — particularly important for first experiences or higher doses
• A safe, private, comfortable physical environment
• Clear intention set in advance
• An integration plan for the days following the experience

✅ Dose Awareness

For most people, a dose of 1 to 3 micrograms per kilogram of body weight is enough to produce a moderate trip. If you haven’t used LSD before, starting with a smaller dose is important — and without chemical testing, it’s impossible to know exactly how much LSD is in any product you choose to take. Reagent testing kits (Ehrlich test) can confirm the presence of an indole compound but cannot determine dose.

✅ Set and Setting

Your mindset and your environment are the two most powerful determinants of whether an LSD experience is positive or difficult. Your current mood and emotional state are amplified dramatically by LSD — if significant anxiety, unresolved grief, or interpersonal conflict is present going in, it will likely surface during the trip. Choose your environment, your company, and your day carefully.

✅ If Things Get Difficult

The primary tool for a difficult LSD experience is surrender rather than resistance. Resisting a difficult psychedelic experience amplifies it. Accepting it — moving toward it rather than away from it — tends to allow it to pass. The key harm-reduction reminder: no one has ever died from a normal LSD experience. Whatever you are experiencing is temporary. The molecule will come loose from its receptor binding and the experience will end.

✅ Integration Is Non-Negotiable

The 24–72 hours following an LSD experience are a critical window for integration. Journal. Sleep. Move your body. Speak with a trusted friend or therapist about what emerged. For our complete guide to psychedelic integration, read our Integration Guide.

Frequently Asked Questions

Why does LSD last so much longer than mushrooms?

The primary reason is LSD’s unique receptor binding mechanism. When LSD molecules land on 5-HT2A receptors, the receptor physically closes over the molecule, trapping it in place. The experience continues until those molecules work free on their own — which can take 6 to 15 hours. Psilocin (the active metabolite of psilocybin) does not bind with the same locked persistence, which is why mushroom trips typically last 4–6 hours.

What actually causes visual hallucinations on LSD?

Neuroimaging research from Imperial College London showed that under LSD, increased blood flow to the visual cortex and dramatically expanded primary visual cortex (V1) functional connectivity correlate strongly with visual hallucinations. The brain’s intrinsic visual activity — normally suppressed by top-down filtering — breaks through into conscious awareness. The visuals are generated by the brain itself, not by external stimuli. The eyes are just the canvas.

Is ego dissolution dangerous?

Ego dissolution is not dangerous in the sense of causing brain damage or physical harm. It can be profoundly disorienting, and for some people it is frightening. For others it is described as the most profound and positive experience of their lives. The experience of ego dissolution appears to be associated with lasting improvements in well-being, openness, and life satisfaction in clinical research. The critical factor is preparation, context, and the presence of a trusted sitter if the experience becomes overwhelming.

Does LSD cause permanent brain damage?

There is no credible scientific evidence that LSD at normal doses causes permanent brain damage. LSD is considered non-toxic at standard doses, and death from LSD alone is extremely rare. The primary risks are psychological — bad trips, HPPD (hallucinogen persisting perception disorder, which occurs in a small minority of users), and triggering of latent psychiatric conditions in those predisposed. These risks are real and worth taking seriously, but they are not the same as structural brain damage.

How is LSD different from a bad trip?

A “bad trip” is not a different chemical event — it’s the same neurological experience with a different emotional and psychological content. The amplification of emotion, dissolution of ego, and loss of ordinary perceptual filters are identical. What differs is the material that surfaces, the person’s relationship to it, and their capacity to surrender to the experience rather than resist it. A challenging LSD experience can be among the most therapeutically meaningful — when approached with the right tools, support, and integration framework.

The Bottom Line

Your brain on LSD is not broken. It is not malfunctioning. It is operating at maximum capacity with its normal constraints temporarily removed.

For twelve hours, the brain’s usual hierarchical order — the filtering, the categorising, the protecting, the self-narrating — is dramatically relaxed. What floods in is raw experience: more sensory, more emotional, more connected, more present, and simultaneously more uncertain and more real than ordinary consciousness typically allows.

The neuroscience of this process is among the most fascinating in modern medicine. The 5-HT2A receptors locking LSD in place. The thalamic gatekeeper failing to filter. The default mode network losing its grip on the self. The global brain connectivity exploding. The control energy landscape flattening into radical freedom of state.

And then, slowly, over twelve hours, reality reassembles — but not quite the way it was before. Because the brain that comes out the other side is not the same brain that went in. New connections have been built. Old patterns have been interrupted. Something has been seen that cannot be unseen.

That, hour by hour, is what happens to your brain on LSD.

Curious about exploring psychedelics safely and intentionally? Browse our full selection of magic mushrooms, or read our complete Microdosing 101 Guide to start smaller and more gently.

Sources

1. Carhart-Harris, R.L. et al. (2016) — “Neural correlates of the LSD experience revealed by multimodal neuroimaging” — PNAS — https://pubmed.ncbi.nlm.nih.gov/27071089/
2. Tagliazucchi, E. et al. (2016) — “Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution” — Current Biology — https://pubmed.ncbi.nlm.nih.gov/27085214/
3. Schmid, Y. et al. (2021) — “Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects” — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/
4. Liechti, M.E. et al. (2017) — “Long-lasting subjective effects of LSD in normal subjects” — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC5813062/
5. Suárez-Pinilla, M. et al. (2025) — “The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic State” — Human Brain Mapping — https://pmc.ncbi.nlm.nih.gov/articles/PMC11979361/
6. Singleton, S.P. et al. (2022) — “Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain’s control energy landscape” — Nature Communications — https://www.nature.com/articles/s41467-022-33578-1
7. Carhart-Harris, R.L. & Friston, K.J. (2019) — “REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics” — Pharmacological Reviews
8. Ly, C. et al. (2018) — “Psychedelics promote structural and functional neural plasticity” — Cell Reports
9. Imperial College London (2016) — “The brain on LSD revealed: first scans show how the drug affects the brain” — https://www.imperial.ac.uk/news/171699/the-brain-lsd-revealed-first-scans/
10. Wikipedia — LSD — Pharmacology and Pharmacokinetics — https://en.wikipedia.org/wiki/LSD
11. Healthline — “How Long Does Acid Last?” — https://www.healthline.com/health/how-long-does-acid-last
12. Health Canada — LSD — https://www.canada.ca/en/health-canada/services/substance-use

Disclaimer: This blog is for educational and harm reduction purposes only and is not medical advice. LSD is a controlled substance in many jurisdictions. Always research the laws in your area before proceeding.

If you’ve spent any time in the microdosing world, you’ve almost certainly heard the name Paul Stamets. And if you’ve heard his name, you’ve almost certainly heard about the Stack.

The Stamets Protocol — a specific combination of psilocybin, Lion’s Mane mushroom, and niacin — has become one of the most talked-about, debated, and widely practiced microdosing regimens in the world. Silicon Valley professionals microdose it for cognitive edge. Depression sufferers use it as a therapeutic bridge. Neuroscience enthusiasts follow it for its neuroplasticity potential. And thousands of ordinary people use it simply because they heard Paul Stamets describe it on a podcast and couldn’t stop thinking about it.

But what exactly is the Stamets Stack? What does each ingredient actually do? How does the combination work? And most importantly — what does the science actually say?

This blog breaks it all down. No hype, no oversimplification — just a clear, honest look at one of the most interesting neurochemical experiments happening in kitchens and capsule makers around the world right now.

Who Is Paul Stamets?

Before we get into the Stack itself, it helps to understand who developed it and why.

Paul Stamets is one of the most decorated and prolific mycologists alive today. Author of six books on mushrooms including the landmark Psilocybin Mushrooms of the World, Stamets has spent decades studying the medicinal, ecological, and neurological potential of fungi. He holds over 20 mushroom-focused patents. He starred in the documentary Fantastic Fungi. He runs Fungi Perfecti, one of the most respected medicinal mushroom companies in North America. And he has dedicated the latter part of his career to advocating for the responsible scientific investigation of psilocybin.

Stamets introduced the idea of stacking psilocybin, lion’s mane, and niacin as a way to promote what he calls “epigenetic neurogenesis” — suggesting that the combination could help the brain grow new cells and pathways. He was motivated significantly by the alarming rise of neurodegenerative conditions like Alzheimer’s disease.

In 2018, Stamets filed a formal patent application with the U.S. Patent and Trademark Office for a composition combining psilocybin or psilocin with erinacines or hericenones (Lion’s Mane bioactives) and niacin — claiming it as a unique method for enhancing neuroregeneration and cognition. The patent describes methods for “enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning” using this combination.

That’s the origin story. Now let’s get into the science of each ingredient.

Ingredient #1 — Psilocybin: The Neuroplasticity Catalyst

Psilocybin is the star of the Stack. In the Stamets Protocol, it’s used at microdose levels — sub-perceptual amounts that produce no psychedelic effects whatsoever, but appear to produce meaningful neurological changes.

A standard microdose of psilocybin in the Stamets Stack is approximately 0.1 to 0.3 grams of dried Psilocybe cubensis — roughly 1/10th to 1/20th of a recreational dose. At these levels, you won’t experience visual distortion, ego dissolution, or any significant alteration of consciousness. What you may notice is a subtle lift in mood, a slight sharpening of focus, and a feeling of mental flexibility that’s hard to precisely describe but consistently reported.

At the pharmacological level, psilocybin is converted in the body to psilocin, which binds to serotonin 2A receptors (5-HT2A) in the prefrontal cortex. At microdose levels, this activation is gentle — but it’s still triggering the same fundamental neuroplasticity cascade that makes high-dose psilocybin so remarkable.

Specifically, psilocybin at even sub-perceptual doses is believed to encourage neuroplasticity — the brain’s ability to reorganize and form new neural connections. Research from Yale University published in Neuron in 2021 showed that a single dose of psilocybin produced approximately a 10% increase in dendritic spine density in the frontal cortex of mice — new physical connections between neurons — that persisted for at least a month. That’s the structural change Stamets is trying to support chronically and gently with the microdosing protocol.

Stamets also theorized specifically that psilocybin at low doses creates a “window” of enhanced neuroplasticity — and that this window is when Lion’s Mane’s nerve growth factors can most effectively build and reinforce new neural structures. Psilocybin opens the door; Lion’s Mane walks through it.

For a full deep dive into psilocybin’s neuroplastic effects, read our blog on how psilocybin grows new brain connections.

Ingredient #2 — Lion’s Mane: The Neural Builder

Lion’s Mane (Hericium erinaceus) is the non-psychedelic powerhouse of the Stack — and the ingredient that most clearly complements psilocybin’s effects at a molecular level.

Lion’s Mane is a shaggy, tooth-like fungus that has been used in traditional Chinese medicine for centuries and naturally grows in North America, Europe, and Asia. What makes it remarkable from a neuroscience perspective is its unique bioactive compounds: hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both classes of compounds have been shown in preclinical research to stimulate the production of Nerve Growth Factor (NGF).

NGF is a protein that supports the survival, growth, and maintenance of nerve cells — essentially biological fertilizer for your neurons. It promotes the formation of new neural connections, supports the health of existing ones, and plays a critical role in the maintenance of the basal forebrain cholinergic system — the brain region most devastated by Alzheimer’s disease.

Research published in PubMed confirmed that hericenones and erinacines isolated from Lion’s Mane can induce NGF synthesis in nerve cells. Crucially, both hericenones and erinacines can easily cross the blood-brain barrier — which means they don’t just circulate in the bloodstream but actively reach and act on brain tissue.

Multiple studies have examined Lion’s Mane’s clinical effects:

• A 2009 double-blind clinical trial showed improvements in mild cognitive impairment in adults aged 50–80 after 16 weeks of Lion’s Mane supplementation. The improvements were observed throughout the trial but not at the follow-up 4 weeks after cessation — suggesting prolonged supplementation is necessary to maintain benefits.
• Animal studies have shown that Lion’s Mane extract reduces anxiety and depressive behaviors by promoting hippocampal neurogenesis in the adult mouse brain.
• A 2023 study in the Journal of Neurochemistry found that hericerin derivatives from Lion’s Mane activate a pan-neurotrophic pathway in central hippocampal neurons, converging to ERK1/2 signaling and enhancing spatial memory.
• Erinacine A, one of the most studied compounds from Lion’s Mane mycelium, has been shown in multiple animal models to reduce amyloid-beta deposition associated with Alzheimer’s disease, and in a 49-week human trial to produce improvements in Mini-Mental State Examination scores in patients with mild Alzheimer’s.

Stamets has specifically called Lion’s Mane the “second smart mushroom,” emphasizing that it “reinforces psilocybin’s ability to occasion neurogenesis.” The rationale is elegant: psilocybin creates the neuroplastic conditions for new neural growth, while Lion’s Mane provides the NGF that fuels that growth and gives it structural support.

By including Lion’s Mane in the stack, Stamets aimed to provide the brain with building blocks for regeneration and cognitive enhancement — not just creating neuroplasticity, but filling it with meaningful biological material.

Curious about our Lion’s Mane and functional mushroom options? Explore our full microdose capsule collection.

Ingredient #3 — Niacin: The Delivery Driver

Of the three ingredients, niacin is the one that raises the most eyebrows. It’s a B vitamin. Why is a B vitamin in a neurogenesis stack?

This is where Stamets’ thinking gets genuinely creative.

Niacin (Vitamin B3), specifically in its flushing form — nicotinic acid — causes a phenomenon called the niacin flush when taken at doses of 50mg or higher. This flush is a prickly, warm, reddening sensation caused by the release of prostaglandins that widen blood vessels and dilate capillaries throughout the body. Within 15–20 minutes of taking niacin, blood flow to the skin and peripheral tissues surges noticeably.

Stamets’ hypothesis is that this vasodilation does something critically important: it drives the active compounds of both psilocybin and Lion’s Mane to the far reaches of the nervous system — to the nerve endings in the peripheral nervous system where, according to Stamets, the majority of neurogenesis actually occurs. Stamets reports that niacin works as a flushing agent and carries compounds across the blood-brain barrier, helping to distribute the psilocybin and Lion’s Mane deeper into the brain and nervous system, enhancing their healing potential.

Stamets also notes that psilocybin tends to mildly constrict blood vessels, while niacin dilates them — making niacin a pharmacological counterbalance that potentially improves the bioavailability and distribution of psilocin throughout the nervous system.

Importantly, Stamets specifies using flushing niacin (nicotinic acid) — not the “no-flush” form sold as niacinamide. The flush is not a side effect to be avoided. It is the mechanism. Non-flushing versions of vitamin B3 do not offer the same delivery benefits and are not part of this protocol.

Beyond its delivery role, niacin has independently documented brain health benefits. One large epidemiological study found that higher dietary niacin intake was associated with a lower risk of Alzheimer’s disease and age-related cognitive decline. Niacin is also essential for cellular energy metabolism as a precursor to NAD⁺, plays a role in DNA repair and cell signalling, and has anti-inflammatory properties.

Stamets has also noted a clever harm-reduction feature built into niacin’s inclusion: the flush acts as a deterrent to high-dose misuse. If someone attempts to take a full psychedelic dose alongside a high niacin dose, the intense, uncomfortable flush — deep redness, itching, and burning sensation — will make that experience deeply unpleasant and discourage repetition. The niacin acts, in his words, as a built-in “anti-abuse” mechanism.

The Synergy: Why Three Is Greater Than One

The power of the Stamets Stack lies not in each ingredient individually — but in the theorized interaction between all three. Here’s how Stamets envisions they work together:

Psilocybin — at microdose levels — binds to 5-HT2A receptors in the prefrontal cortex, triggering a cascade of neuroplastic changes. New dendritic spines begin forming. The brain enters an enhanced state of structural flexibility.

Lion’s Mane simultaneously floods the brain with hericenones and erinacines — compounds that stimulate NGF and BDNF production. These growth factors provide the biological “materials” needed to build new neural connections. The psilocybin-induced neuroplasticity window gives those growth factors more surface area to work with.

Niacin opens the circulation highways, driving both sets of compounds deeper into the nervous system — particularly to the peripheral nerve endings where Stamets believes neuroregeneration is most needed and where the compounds might otherwise struggle to penetrate.

In his own words from the patent application: “psilocin and its analogs are neurotransmitters, and substitute for serotonin, acting as an agonist exciting serotonin receptors, their ability to enhance neurotransmission while in combination with nerve growth factors such as erinacines and hericenones, provides a unique opportunity for spurring neurogenesis. When combined with niacin, which causes nerve ending excitement, and additionally combined with mushroom and plant extracts, compounded neurogenic benefits are anticipated.”

In short, the theory is: psilocybin opens the window, Lion’s Mane builds through it, and niacin makes sure delivery reaches the furthest corners of the house.

What Does the Science Actually Say?

This is the question that separates enthusiasts from researchers — and the honest answer is: promising but not yet proven.

Here’s what we actually know:

On psilocybin alone: The neuroplasticity evidence is robust and growing. The 2021 Yale study on dendritic spine density, the 2025 Cornell study on psilocybin rewiring entire brain networks, and multiple human clinical trials at Johns Hopkins confirm that psilocybin produces real, measurable, lasting structural brain changes. The evidence for psilocybin’s neuroplasticity effects — even at low doses — is the strongest leg of the Stack.

On Lion’s Mane alone: The preclinical evidence (primarily in cell cultures and animal models) for NGF stimulation via hericenones and erinacines is well-established. Human clinical data is more limited but encouraging — particularly the 2009 cognitive impairment trial and emerging Alzheimer’s research. A 2022 observational study published in Nature Scientific Reports found that microdosers using psilocybin combined with Lion’s Mane and niacin reported better mental health outcomes than those microdosing psilocybin alone.

On the full Stack: This is where the evidence gap becomes clear. The full synergistic combination — all three components together — has not yet been the subject of a robust, placebo-controlled human clinical trial. A large 2022 observational study of nearly 1,000 microdosers found that those using the Stamets Stack reported better mental health outcomes than psilocybin-only microdosers, and critically, adults over 55 who used the full Stack exhibited greater improvements in psychomotor performance compared to psilocybin alone.

However, the researchers correctly acknowledged that this was observational, self-reported data. The improvements could reflect expectancy effects (placebo), reporting bias, or genuine pharmacological synergy — it’s not possible to distinguish between them without a controlled trial.

The honest scientific assessment: each ingredient has individual evidence, a promising observational signal exists for the combination, and rigorous controlled trials are the next necessary step. Stamets himself has co-founded MycoMedica Life Sciences, which has raised $60 million and is working toward exactly these clinical trials.

The Protocol: How to Actually Do It

The Dosing Schedule

The Stamets Protocol follows a rhythmic cycle designed to prevent tolerance buildup in the psilocybin component while allowing the neuroplastic changes to stabilize and mature:

4 days ON → 3 days OFF

During the 4 ON days, you take all three components. During the 3 OFF days, you take nothing (though you can continue Lion’s Mane on off days if desired, as it is non-psychoactive and tolerance to it is not a concern).

This weekly cycle is typically repeated for 4 consecutive weeks (one month), followed by a reset period of 2–4 weeks with no psilocybin. Many microdosers repeat multiple rounds over months or choose to cycle indefinitely with regular reset periods.

The Doses

Based on Stamets’ recommendations and the most commonly reported protocol in the microdosing community:

Psilocybin (dried Psilocybe cubensis):
0.1g to 0.3g dried mushrooms — equivalent to approximately 1–3mg of psilocybin. This is the foundational microdose range. Start at 0.1g and adjust based on your sensitivity. If you feel anything perceptual at all, your dose is too high — reduce it.

Lion’s Mane extract:
500mg to 1000mg of a quality Lion’s Mane extract. Stamets recommends mycelium-based extracts as potentially most beneficial for neurological applications, given that erinacines (the most potent neuroactive compounds) are found in the mycelium rather than the fruiting body. That said, fruiting body extracts containing hericenones also have substantial research support.

Niacin (flushing nicotinic acid — not niacinamide):
100mg to 200mg. Start at 50mg if you are sensitive to flushing. Work up gradually. Do not substitute with “no-flush” niacinamide — it does not produce the vasodilation that is central to Stamets’ delivery theory.

Timing

Most practitioners take all three components simultaneously in the morning, on an empty or light stomach, to align the niacin flush with the subtle onset of psilocybin’s effects. Some prefer to take niacin 10–15 minutes before the other two to allow the vasodilation to begin before the psilocybin is absorbed.

What to Expect

On a well-calibrated Stamets Stack, you should feel nothing dramatic. That’s the point. Common reports from long-term stackers include:

• A gentle warmth or flush 15–20 minutes after dosing (niacin)
• A barely perceptible brightening of mood or mental clarity within 60–90 minutes
• Slightly enhanced creative thinking or problem-solving flexibility
• A mild feeling of being “more present” or engaged
• Reduced emotional reactivity over the course of weeks
• Gradual improvements in focus and memory over a 4-week protocol

If you feel visually altered, anxious, dissociated, or noticeably “high” — your psilocybin dose is too high. Reduce it immediately. The goal is sub-perceptual. Always.

Who Is the Stamets Stack For?

Based on community data and the theoretical framework of the Stack, it appears most relevant for:

People interested in cognitive enhancement: The combination of neuroplasticity (psilocybin), NGF stimulation (Lion’s Mane), and improved delivery (niacin) creates a theoretically compelling stack for those seeking to optimize focus, creativity, and memory.

People managing depression or anxiety: Microdosing psilocybin has shown small-to-medium improvements in mood and mental health in observational studies. The Stack adds Lion’s Mane’s independently documented mood-supporting and anti-depressive effects — a meaningful addition for those looking for gentle, consistent support.

Older adults interested in neurological health: The 2022 observational study found that adults over 55 using the full Stack showed greater improvements in psychomotor performance than those using psilocybin alone — one of the most concrete signals to date that the combination may have age-specific benefits.

Anyone interested in long-term brain health: Stamets was motivated primarily by neurodegenerative disease prevention. The combination of psilocybin’s neuroplasticity, Lion’s Mane’s NGF stimulation, and niacin’s circulatory support represents a multi-angle approach to maintaining and enhancing brain function over time.

Who it may NOT be for:

• People currently on SSRIs or MAOIs (significant drug interactions possible)
• People with a personal or family history of psychosis or schizophrenia
• People with a history of liver disease (niacin at high doses can affect liver enzymes)
• Pregnant or breastfeeding individuals
• Anyone with blood pressure sensitivity (niacin’s vasodilation can interact with blood pressure medications)

Always consult a healthcare professional before beginning any microdosing protocol. And always check our full Microdosing 101 Guide before getting started.

The Stamets Stack vs. The Fadiman Protocol

For those already familiar with microdosing, you may wonder how the Stamets Stack compares to the better-known Fadiman Protocol — named after psychedelic researcher Dr. James Fadiman.

The Fadiman Protocol is simpler: 1 day ON, 2 days OFF, psilocybin only. No supplemental stack.

The key differences:

Frequency: Stamets doses more frequently (4 days on vs. 1 day on). This increases total psilocybin exposure but potentially also tolerance risk — mitigated in the Stack by the 3-day break.

Complexity: Stamets adds Lion’s Mane and niacin; Fadiman uses psilocybin alone. This makes the Stack harder to attribute specific effects to any single component.

Goal orientation: Fadiman’s protocol was developed primarily for general wellbeing and mental health enhancement. The Stamets Stack is specifically oriented toward neurogenesis and long-term neurological optimization.

Evidence: Both protocols have observational data supporting benefits, but neither has robust placebo-controlled clinical trial evidence for the specific regimen as a whole.

For a full comparison of microdosing protocols, read our Microdosing 101 Guide.

Practical Tips for Running the Stamets Stack

Start Low, Move Slow

Many people make the mistake of starting at the top of the dose range. Psilocybin sensitivity varies enormously. Begin at 0.1g, 50mg niacin, and 500mg Lion’s Mane. Evaluate for one full week before considering any adjustment.

Use Flushing Niacin — Not Niacinamide

This cannot be overstated. Niacinamide is the non-flushing form of B3 — it does not cause vasodilation and does not serve Stamets’ delivery hypothesis. If you’re not flushing, you’re not running the Stack as intended.

Track Your Experience

Keep a simple daily journal. Note mood, focus, creativity, sleep quality, and any unusual sensations. Over a 4-week cycle, patterns emerge that are difficult to perceive day by day but obvious in retrospect.

Choose Quality Lion’s Mane

The Lion’s Mane supplement market is full of products with poor potency, mycelium-on-grain products with minimal erinacine content, or adulterated formulas. Stamets himself recommends mycelium-based extracts for maximum erinacine content. Choose products that clearly specify their extraction method and active compound concentration.

Respect the OFF Days

The 3-day break in the Stamets Protocol serves two purposes: preventing psilocybin tolerance, and allowing the neuroplastic changes stimulated by the ON days to consolidate and mature. Skipping the OFF days undermines both purposes.

Plan Your Integration

Even at microdose levels, the Stamets Stack can surface unexpected emotional material over the course of a full protocol. Journaling, meditation, and regular reflection during the 4-week cycle will help you integrate what arises. Read our Integration Guide for full support.

What Stamets Is Really Claiming — And What He Isn’t

It’s worth being clear about the distinction between what Stamets has theorized, what he has claimed in patents, and what science has confirmed.

What Stamets claims: That the combination of psilocybin, Lion’s Mane, and niacin synergistically promotes neurogenesis, repairs neurological damage, and could benefit conditions ranging from Alzheimer’s and PTSD to general cognitive enhancement in healthy individuals.

What science has confirmed: Each ingredient individually has meaningful neurological activity. Psilocybin promotes neuroplasticity with growing evidence. Lion’s Mane stimulates NGF and BDNF with strong preclinical and growing human evidence. Niacin supports circulation and brain health with independent evidence. The combination has shown a promising signal in a large observational study. The specific synergistic mechanism Stamets proposes has not yet been formally tested in a controlled human trial.

Stamets has been criticized by some in the scientific community for the breadth of his patent claims and the ahead-of-evidence enthusiasm of his public statements. Those criticisms are fair. But the core idea — that combining a neuroplasticity catalyst, a nerve growth factor stimulator, and a circulatory enhancer might produce additive or synergistic neurogenic benefits — is not only plausible but scientifically grounded in the known properties of each compound.

The rigorous trials are coming. The signal is there. And until the controlled data arrives, the Stack remains one of the most scientifically coherent and well-reasoned approaches to neurological optimization available to curious, harm-reduction-oriented individuals.

Frequently Asked Questions

Do I need all three ingredients for the Stack to work?

Stamets designed the Stack with all three working synergistically. However, many people run psilocybin + Lion’s Mane without niacin if the flush is uncomfortable or contraindicated. Some run Lion’s Mane + niacin without psilocybin due to legal restrictions. Each combination has theoretical value, but the full three-ingredient Stack is Stamets’ specific protocol.

Can I take Lion’s Mane on my OFF days?

Yes. Lion’s Mane is non-psychoactive and does not produce tolerance. Many practitioners take it daily regardless of psilocybin dosing days to maintain consistent NGF stimulation.

Will the niacin flush go away over time?

Yes. With regular use, niacin tolerance develops and the flush diminishes — sometimes disappearing almost entirely. Some practitioners take a break from niacin periodically to restore the flush, believing it indicates the vasodilatory mechanism is actively engaged.

Can I use Lion’s Mane capsules instead of fresh mushroom?

Yes. Fresh Lion’s Mane is excellent if available, but quality extract capsules are the most practical format. Stamets recommends mycelium-based extracts for higher erinacine content, though fruiting body extracts with hericenones are also effective. Aim for 500mg–1000mg of a quality extract daily.

Is this the same as the Fadiman Protocol?

No. The Fadiman Protocol uses psilocybin alone on a 1-day-on, 2-days-off schedule. The Stamets Protocol adds Lion’s Mane and niacin on a 4-days-on, 3-days-off schedule. Both are legitimate microdosing protocols with different theoretical bases and practical rhythms.

How do I source the psilocybin component in Canada?

Browse our full selection of psilocybin microdose capsules at Shroom Bros — precisely dosed, consistent quality, and formulated for exactly this kind of protocol.

The Bottom Line

The Stamets Stack is not a magic bullet. It’s not a pharmaceutical. It’s not a proven cure for anything.

What it is: a thoughtfully constructed, theoretically grounded, and increasingly well-observed protocol that combines three compounds with individually meaningful neurological properties — in a configuration designed to address the brain’s neuroplasticity, neurogenesis, and circulatory health simultaneously.

Psilocybin creates the neuroplastic conditions. Lion’s Mane builds through them with nerve growth factors. Niacin drives both compounds deeper into the nervous system where the real work happens. Together, the theory goes, they do something none of them can do alone.

The controlled trials will come. The signal is already there. And for those who approach it with intention, patience, and appropriate medical guidance, the Stamets Stack represents one of the most genuinely interesting experiments in modern cognitive wellness — grounded in the ancient wisdom of fungi and the cutting edge of neuroscience at the same time.

Happy microdosing.

Ready to start? Browse our full selection of magic mushrooms and microdose capsules, or read our complete Microdosing 101 Guide before you begin.

Sources

1. Stamets Patent Application (2018) — “Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin” — https://patents.google.com/patent/US20180021326A1/en
2. Rootman et al. (2021) — “Adults who microdose psychedelics report health-related motivations and lower levels of anxiety and depression compared to non-microdosers” — Scientific Reports — https://pmc.ncbi.nlm.nih.gov/articles/PMC8602275/
3. Rootman et al. (2022) — “Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls” — Scientific Reports — https://www.nature.com/articles/s41598-022-14512-3
4. Shao et al. (2021) — “Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo” — Neuron — https://pubmed.ncbi.nlm.nih.gov/34228959/
5. Lai et al. (2013) — “Neurotrophic properties of the Lion’s mane medicinal mushroom, Hericium erinaceus” — PubMed — https://pubmed.ncbi.nlm.nih.gov/24266378/
6. Ratto et al. (2019) — “Hericerin derivatives activates a pan-neurotrophic pathway in central hippocampal neurons” — Journal of Neurochemistry — https://onlinelibrary.wiley.com/doi/10.1111/jnc.15767
7. Phan et al. (2023) — “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines” — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC5987239/
8. Quantified Citizen / Paul Stamets (2022) — Microdosing Study with Stamets Stack Results — https://finance.yahoo.com/news/latest-psilocybin-microdosing-study-powered-170000932.html
9. DoubleBlind Magazine — “The Stamets Stack: Microdosing for Brain Health” — https://doubleblindmag.com/stamets-stack/
10. Yale School of Medicine — Paul Stamets January 2023 Seminar — https://medicine.yale.edu/media-player/stamets-yale-seminar/
11. Zamnesia — “What Is Paul Stamets’ Microdosing Stack?” — https://www.zamnesia.com/blog-paul-stamets-protocol-n2010
12. Health Canada — Psilocybin and Psilocin — https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html

Disclaimer: This blog is for educational and harm reduction purposes only and is not medical advice. Always consult a healthcare professional before beginning any supplement or microdosing protocol.

There’s a question that comes up constantly in the mushroom community: “I took 1 gram and it hit way harder than when I ate dried mushrooms at the same dose. What gives?”

It’s not your imagination. It’s not a batch that was somehow stronger. It’s not a placebo.

When you consume psilocybin in chocolate form — or in a gummy, or in a capsule — your body processes it differently than it does when you chew through a handful of dried Psilocybe cubensis. The matrix the compound is delivered in changes everything: the onset, the peak, the smoothness, the intensity, and even the duration.

This blog breaks down exactly why 1 gram in a chocolate bar is not the same as 1 gram of raw dried mushrooms — and what that means for how you should approach dosing.

First, Let’s Talk About What Psilocybin Actually Is

Before we get into the chocolate science, a quick primer.

Psilocybin is the compound in magic mushrooms that makes them magic. But here’s the thing — psilocybin itself is technically inactive. It’s what pharmacologists call a prodrug. When you ingest it, your body converts it into psilocin, the compound that actually binds to your serotonin receptors and produces the psychedelic experience.

This conversion happens primarily in the liver through a process called dephosphorylation. The speed and completeness of that conversion — and how efficiently psilocin enters your bloodstream — is where the differences between consumption methods start to emerge.

Pharmacokinetic research shows that after oral administration, psilocybin is detectable in the bloodstream within 20 to 40 minutes, with psilocin peak levels typically arriving between 1 and 3 hours depending on the individual and method of consumption. But that window shifts significantly depending on what vehicle is carrying the psilocybin into your body.

If you want a broader overview of how psilocybin affects you once it’s in your system, our guide on How Shrooms Make You Feel is a great foundation.

The Real Reason Dried Mushrooms Are Harder to Digest Than You Think

Here’s something most people don’t think about: when you eat dried mushrooms, you’re not just eating psilocybin. You’re eating an entire organism — cell walls, fibres, proteins, polysaccharides, and all.

The cell walls of fungi are made of chitin (pronounced “KYE-tin”) — the same tough structural compound found in crab shells and insect exoskeletons. Chitin is notoriously difficult for the human body to break down. Your digestive system doesn’t produce the enzymes needed to fully dissolve it, which means two things happen when you eat raw dried mushrooms:

1. Absorption is delayed and inconsistent. Psilocybin locked inside intact chitin cell walls takes longer to escape into your digestive system, leading to a slower, more unpredictable onset.
2. Nausea is common. Chitin irritates the gastrointestinal tract. It triggers inflammatory and immune responses in the gut, which contributes to the infamous “gut rot” that many mushroom users experience in the first 30–60 minutes of a trip.

As mycologist Paul Stamets has noted, “raw mushrooms are largely indigestible because of their tough cell walls, mainly composed of chitin.” Raw mushrooms may even contain heat-sensitive compounds and pathogens that the body tries to expel — which is part of why nausea can be intense with unprocessed dried material.

This is the foundational reason why edible forms of psilocybin — chocolates, gummies, capsules, and teas — can feel so different. They bypass or reduce the chitin problem entirely.

What Happens When Mushrooms Are Processed Into Chocolate

When mushrooms are prepared for a chocolate bar, the process typically involves grinding the dried mushrooms into a fine powder and incorporating that powder into a chocolate matrix. This matters for several reasons.

1. Cell Wall Disruption Increases Bioavailability

Grinding dried mushrooms into a powder mechanically ruptures the chitin cell walls that normally slow absorption. More surface area is exposed, which means psilocybin leaches out into your digestive system more quickly and more completely than it would from a whole or coarsely chewed mushroom.

2. Fat Content in Chocolate Affects Absorption Timing

Chocolate contains significant amounts of fat — primarily cocoa butter. Fats slow gastric emptying, which means the contents of your stomach move more gradually into your small intestine (where most absorption occurs). This produces a classic edible effect: a delayed onset followed by a more sustained, even release of the active compound.

The fats and sugars in the chocolate matrix can slow gastric emptying, potentially delaying initial effects while extending overall duration. This is why many people describe mushroom chocolate experiences as having a softer, more gradual come-up compared to eating raw dried mushrooms — which tend to hit harder and faster on an empty stomach.

3. Gummies Are Different Again

Gummies add another layer of distinction. Many high-quality mushroom gummies are made with psilocybin extract rather than ground whole mushroom matter. This means there’s no chitin to deal with at all — just the active compound in a gelatin or pectin delivery matrix.

Gummies often contain just psilocybin extract and no mushroom matter, which is why you generally shouldn’t experience the nausea or muscle cramps that can come with raw mushroom consumption. The tradeoff is that without the full spectrum of compounds found in whole mushrooms, you may lose some of the entourage effects that whole-fruiting-body consumption provides.

The Stomach Environment and Why It Changes Everything

One factor almost nobody talks about when comparing edible formats is the role of stomach acidity and fullness at the time of consumption.

Psilocybin conversion to psilocin happens largely in the liver — but the speed at which psilocybin reaches the liver depends heavily on how quickly it moves through your stomach. An empty, acidic stomach is a very different environment than one that’s full and buffered by fats and carbohydrates.

• Empty stomach + dried mushrooms: Fast gastric emptying, chitin irritation, potentially intense and fast onset with significant nausea risk.
• Full stomach + mushroom chocolate: Slowed gastric emptying due to fat and sugar content, longer onset (sometimes 90 minutes to 2 hours), smoother peak, reduced nausea.
• Empty stomach + mushroom chocolate: Faster than full-stomach chocolate, still smoother than raw dried mushrooms due to powder format and lack of raw fungal matter.

This is critical for dosing. If you ate 1 gram of dried mushrooms on an empty stomach last time and now you’re eating 1 gram of mushroom chocolate after a meal — you are having a fundamentally different pharmacokinetic experience, even at the same gram weight.

The Cacao Chemistry: Why Chocolate Isn’t Just a Delivery Vehicle

Here’s where things get genuinely fascinating. Chocolate isn’t just a neutral wrapper for psilocybin. The cacao itself is pharmacologically active — and it may directly potentiate the effects of psilocybin.

Cacao as a Mild MAOI

Cacao contains naturally occurring compounds called monoamine oxidase inhibitors (MAOIs). Specifically, research has identified tetrahydro-beta-carbolines in cacao — compounds that slow the breakdown of tryptamine alkaloids, including psilocin, in the body.

MAO (monoamine oxidase) is an enzyme responsible for breaking down serotonin and other neurotransmitters — including psilocin — in your gut and bloodstream. When MAO activity is reduced, more psilocin survives and remains active for longer. This is the same basic mechanism behind ayahuasca, where the MAOI-containing plant prevents DMT from being broken down before it can produce effects.

Cacao is not a strong MAOI by any means. But in sufficient quantities, it is thought to produce a mild MAOI effect that can potentiate and extend the effects of psilocybin. The Aztecs were almost certainly aware of this synergy — even if they didn’t have the biochemical language to describe it.

Theobromine: The Heart-Opener

Cacao beans contain up to 40–50% fat and are rich in theobromine — one of the main compounds responsible for their uplifting and stimulating properties. Theobromine is a mild stimulant that can complement the energizing aspects of a psilocybin experience, while also acting as a vasodilator — meaning it widens blood vessels and increases blood flow throughout the body, including to the brain.

Anandamide and PEA

Cacao also contains anandamide — sometimes called the “bliss molecule” — a naturally occurring cannabinoid that produces feelings of euphoria by reducing pain, stress, and anxiety. Cacao also contains enzyme inhibitors that slow the breakdown of anandamide in the body, prolonging its effects.

Additionally, cacao contains phenylethylamine (PEA), sometimes called the “love molecule,” which produces stimulant and mood-elevating effects. The combination of theobromine, anandamide, PEA, and mild MAOI activity means that the chocolate in your mushroom bar is not passive — it’s contributing its own pharmacological fingerprint to the experience.

This ancient biochemical synergy is almost certainly why the Aztecs combined these two “foods of the gods” for thousands of years in their ceremonial practice.

The Ancient Aztec Combo: They Knew Before We Did

The combination of cacao and psilocybin mushrooms is not a modern invention. Thousands of years ago, the Aztecs and other Mesoamerican cultures were knowingly combining cacao with the transformative power of psilocybin mushrooms in sacred ceremony. This ancient combination was referred to as “cacahua-xochitl” — literally meaning “chocolate-mushrooms.”

The Aztecs combined psilocybin mushrooms with admixtures containing honey, flowers, and herbs, according to records of Aztec history. During the ceremony, the Aztecs would reportedly drink the cacao first, then eat the psilocybin mushrooms with honey.

We now know that cacao contains small amounts of enzyme inhibitors capable of slowing the breakdown of the psychoactive compounds found in psilocybin mushrooms, thereby perpetuating or amplifying the effects. The Aztecs may not have had the biochemical language — but they had thousands of years of empirical observation.

Dosing Mushroom Chocolates: What 1 Gram Actually Means

So with all of this context — what does 1 gram in a chocolate bar actually mean?

The Potency Variable: What Kind of Mushroom Was Used?

Not all mushroom chocolates are created equal. The psilocybin content of magic mushrooms varies enormously — even within the same species. Psilocybin content typically ranges from around 0.5% to 1% of the dried weight of the mushroom, with a range of 0.03% to 1.78%. A 1 gram bar made with Penis Envy — one of the most potent strains available — will hit dramatically harder than a 1 gram bar made with a lower-potency Golden Teacher or B+ strain.

This is a crucial distinction that many consumers overlook. When a bar says “1g,” that’s the weight of mushroom material — not the weight of psilocybin. The actual psilocybin content depends entirely on which strain was used and how it was cultivated.

Check out our breakdown of magic mushroom strains to understand the potency differences between popular varieties.

Distribution: The Hot Spot Problem

Here’s a dirty secret about homemade and low-quality mushroom chocolates: psilocybin doesn’t distribute evenly through chocolate without proper technique.

When mushroom powder is added to melted chocolate without careful, thorough mixing, the powder can clump and settle in certain areas of the bar. This creates what are sometimes called “hot spots” — sections of the bar with significantly more psilocybin than others. You might eat what you think is one square (a quarter gram) and actually consume the equivalent of two grams — or almost nothing.

Professional manufacturers strive to ensure an even distribution of psilocybin throughout chocolate bars, but amateur producers may create hot spots with concentrated doses in specific pieces. This inconsistency is one of the primary reasons why dosing mushroom chocolates can feel so unpredictable — especially with bars from unverified sources.

The Fat-Delay Factor: Why Timing and Fullness Matter

As we covered above, the fat content in chocolate slows gastric emptying. This means:

• Don’t redose too early. Many people make the mistake of eating a square, waiting 45 minutes, feeling nothing significant, and eating another square — only to have both doses hit simultaneously when gastric emptying finally occurs. This is how people accidentally overwhelm themselves on what they thought was a moderate dose.
• Wait at least 90 minutes before considering a redose. Chocolate edibles can take up to two hours to fully onset depending on your metabolism and what else is in your stomach.
• Your last meal matters. A heavy, fatty meal before your chocolate can delay onset even further. A light meal or empty stomach will bring it on faster and more intensely.

The Cacao Potentiation Factor

If you’re comparing your mushroom chocolate experience to a previous dried mushroom experience at the “same” dose — remember to factor in the cacao chemistry. The mild MAOI activity, theobromine, anandamide, and PEA in the chocolate matrix may be contributing to a noticeably stronger or more euphoric experience even before you account for any absorption or distribution differences.

This is especially relevant with ceremonial-grade or high-cacao-percentage chocolate bases. A 70% dark chocolate bar is going to have more active cacao compounds than a milk chocolate base — and may produce a meaningfully different experience at the same mushroom dose.

Practical Dosing Guidelines for Mushroom Chocolates

For Beginners: Start Lower Than You Think You Need To

If you’re new to mushroom chocolates or edibles in general, start with 0.5g–1g and wait a full 90 minutes before evaluating. The delayed onset of fat-based edibles means you need to be patient. A common beginner mistake is to dose at 1g, feel very little at 45 minutes, eat another gram, and then get hit by 2g all at once.

Recreational doses of psilocybin mushrooms are typically between 1.0 and 3.5–5.0 g of dry mushrooms — but in chocolate form, with the factors we’ve discussed, many people find the lower end of that range produces a fuller experience than expected.

For Experienced Users: Scale Cautiously

Even experienced mushroom users should reduce their expected dose by 10–20% when switching from dried mushrooms to chocolate. The smoother, more even absorption — combined with cacao’s mild potentiation — means the same gram weight often produces a more intense experience in chocolate form.

Source Matters Enormously

Given the real risks of uneven distribution in amateur bars, and the documented presence of undisclosed or mislabelled ingredients in unregulated edibles, sourcing your mushroom chocolates from a trustworthy vendor is not optional — it’s essential.

Browse our full selection of mushroom chocolates and mushroom gummies from Shroom Bros — lab-quality sourcing, reliable potency, and consistent distribution every time.

Consider Microdosing Formats for Precision

If consistent, precise dosing is your primary goal — especially for therapeutic or productivity-focused use — microdose capsules offer the most reliable and measurable format. Capsules eliminate the fat-delay variable, the distribution inconsistency, and the cacao potentiation factor, giving you a cleaner baseline from which to calibrate your experience.

For everything you need to know about getting started, read our full Microdosing 101 Guide.

Frequently Asked Questions

Why did my mushroom chocolate hit harder than the same dose of dried shrooms?

Several reasons work together: the mushroom powder in chocolate is more bioavailable than whole dried mushrooms because cell walls are already disrupted; the fat matrix delivers a slower, more complete release; and cacao’s mild MAOI activity, theobromine, and anandamide may genuinely amplify the experience. All of these factors compound on top of each other.

Can I just eat more chocolate to increase the dose?

Yes, but proceed slowly. Because of the delayed onset with fat-based edibles, always wait at least 90 minutes before considering an additional dose. Rushing the redose is the number one cause of accidental overconsumption with mushroom chocolates.

Do mushroom gummies feel different from mushroom chocolates?

Yes, meaningfully so. Gummies — especially those made with psilocybin extract rather than whole mushroom powder — tend to have a faster and more consistent onset, lower nausea risk, and a cleaner come-up without the additional pharmacological contributions of cacao. The trade-off is that they may lack the entourage effect of whole-mushroom products.

Does the percentage of cacao in the chocolate matter?

It can. Higher-cacao-percentage chocolates (70%+ dark chocolate) contain more theobromine, MAOIs, and anandamide than milk chocolate formulations. If you’re eating a ceremonial-grade dark chocolate bar, you may want to start with a slightly lower mushroom dose than you would with a milk chocolate base.

Is heating the mushrooms in the chocolate making the psilocybin weaker?

This is a common concern. The melting point of cacao paste is around 94°F — well below temperatures that degrade psilocybin. Authors of the Psilocybin Chef Cookbook note there’s no hard evidence that typical chocolate-making temperatures meaningfully affect psilocybin content. The benefits of processing (cell wall disruption, reduced nausea) far outweigh any minimal thermal degradation risk in a properly made bar.

The Bottom Line

When you eat 1 gram of psilocybin mushroom chocolate, you are not having the same experience as eating 1 gram of dried mushrooms. You’re consuming a fundamentally different delivery format — one where the mushroom powder has had its cell walls disrupted for better bioavailability, where the fat matrix smooths and extends absorption, and where cacao itself is adding its own mild pharmacological layer to the experience.

The result is typically a softer onset, a longer and more sustained peak, dramatically less nausea — and often a noticeably more intense experience at the same gram weight.

Understanding this isn’t just interesting — it’s essential for dosing intelligently and staying safe. Start lower than you think you need to. Wait longer than you think you should. And respect the fact that the matrix matters as much as the molecule.

Happy tripping.

Curious to explore? Browse our full selection of magic mushrooms, mushroom chocolates, and microdose capsules — or read our full guide on How Different Strains Affect Your Experience before your next session.

Sources

1. Wikipedia — Psilocybin Pharmacokinetics — https://en.wikipedia.org/wiki/Psilocybin
2. Wikipedia — Psilocybin Mushroom Dosing — https://en.wikipedia.org/wiki/Psilocybin_mushroom
3. Recovered.org — Psilocybin Edibles: Chocolate, Gummies & More — https://recovered.org/hallucinogens/psilocybin/psilocybin-edibles
4. California Detox — Mushroom Chocolate Bars — https://californiadetox.com/drug-info/mushroom-chocolate-bars/
5. Soul Lift Cacao — Ceremonial Cacao and Psilocybin Mushrooms — https://soulliftcacao.com/blogs/news/psilocybin-mushroooms-and-ceremonial-cacao-in-psychedelic-therapy
6. Truffle Report — Stacking Psychedelics: Can Chocolate Enhance Your Trip? — https://truffle.report/stacking-psychedelics-can-chocolate-enhance-your-trip/
7. Zamnesia — The Aztec Psychedelic Combo: Mixing Psilocybin With Cacao — https://www.zamnesia.com/blog-aztec-magic-mushrooms-cacao-n383
8. Tripsitter — Cacao & Magic Mushrooms: Why Is This Combination So Powerful? — https://tripsitter.com/cacao-mushrooms/
9. Psychedelic Science Review — Why Do Magic Mushrooms Cause Nausea? — https://psychedelicreview.com/why-do-magic-mushrooms-cause-nausea/
10. Ouroboros Foundation — Psilocybin and Gastrointestinal Distress — https://www.theouroborosfoundation.org/knowledge-base/psilocybin-and-gastrointestinal-distress-what-causes-gut-issues
11. Alchimia Grow Shop — Magic Mushrooms and Stomach Problems — https://www.alchimiaweb.com/blogen/magic-mushrooms-stomach-problems/
12. Hamilton’s Mushrooms — Is Chitin Digestible? — https://hamiltonsmushrooms.com/blogs/the-fungible-content/is-chitin-digestible-it-in-now

Disclaimer: This blog is for educational and harm reduction purposes only and is not medical advice.

There’s a question that comes up a lot in the mushroom community: “Why does a single trip sometimes change the way I feel for weeks or even months afterward?”

It’s a fair question. Psilocybin is out of your system within hours. The trip is over by bedtime. So why do the benefits — the lifted mood, the new perspective, the feeling that something fundamental has shifted — stick around so long after the compound is gone?

The answer, according to a growing body of neuroscience research, is that psilocybin doesn’t just change the way you think. It changes the physical structure of your brain.

We’re talking about real, measurable, microscopic growth — new connections between neurons that weren’t there before. And the most exciting part? These changes happen fast, and they last.

This blog breaks down the science in plain language. No PhD required. Just curiosity.

First, a Quick Brain Anatomy Lesson (We’ll Keep It Simple)

To understand what psilocybin does to your brain, you need to know about three things: neurons, dendrites, and dendritic spines.

Neurons are your brain cells. You have roughly 86 billion of them. They communicate with each other by sending electrical and chemical signals across tiny gaps called synapses.

Dendrites are the branch-like extensions that stick out from each neuron. Think of them like antennae — they receive incoming signals from other neurons.

Dendritic spines are tiny mushroom-shaped bumps that sit along those dendrites. Each spine is a connection point — a place where one neuron receives a signal from another. The more spines you have, and the bigger they are, the more connections your brain can make. More connections means better communication between brain regions, faster processing, and greater cognitive and emotional flexibility.

Here’s the critical part: depression, chronic stress, and anxiety physically shrink and destroy these dendritic spines. People with major depression have measurably fewer spines — especially in the prefrontal cortex, the region responsible for mood regulation, decision-making, and self-awareness. If you want to understand more about how psilocybin interacts with this part of the brain, our blog on How Shrooms Make You Feel is a great starting point.

Depression literally strips your brain of connections. And that’s where psilocybin comes in.

The Yale Study That Changed Everything (2021)

In July 2021, a research team at Yale University published a study in the journal Neuron that sent shockwaves through the neuroscience world. Led by Dr. Alex Kwan, an associate professor of psychiatry and neuroscience, the study provided the first direct evidence that a single dose of psilocybin physically grows new neural connections in a living mammalian brain.

Here’s what they did: using an advanced technique called chronic two-photon microscopy, Kwan’s team tracked 1,820 individual dendritic spines in the frontal cortex of living mice over multiple days. They gave one group a single dose of psilocybin and the other a saline placebo, then watched what happened.

The results were striking.

Within 24 hours of a single psilocybin dose, the mice showed approximately a 10% increase in both the number and size of dendritic spines in the medial frontal cortex — the mouse equivalent of the human prefrontal cortex.

But here’s the part that really made headlines: those new connections were still there a month later.

Dr. Kwan put it plainly: “We not only saw a 10% increase in the number of neuronal connections, but also they were on average about 10% larger, so the connections were stronger as well. It was a real surprise to see such enduring changes from just one dose of psilocybin.”

The study also found that psilocybin reversed stress-related behavioral deficits in the mice and boosted excitatory neurotransmission — meaning not only were the new connections growing, they were actively communicating.

This was huge. For the first time, researchers could literally see psilocybin building new brain architecture, one spine at a time.

Why This Matters for Depression

Remember those dendritic spines we talked about? Depression destroys them. The prefrontal cortex of a person with chronic depression looks physically different under a microscope — fewer spines, thinner dendrites, weaker connections.

Traditional antidepressants like SSRIs work by increasing the availability of serotonin in the brain. But they don’t directly rebuild lost connections. They manage symptoms, often for years, without addressing the underlying structural damage. And they can take 4–6 weeks to produce noticeable effects.

Psilocybin appears to work differently. Instead of just adjusting brain chemistry, it promotes the physical regrowth of the neural infrastructure that depression erodes. And it does it fast — within 24 hours.

This is why a single psilocybin experience can produce antidepressant effects that last weeks or months. It’s not just a chemical mood boost that wears off. The brain has physically rebuilt connections that support healthier patterns of thought and emotion. The hardware has been upgraded, not just the software.

Multiple clinical trials — from Johns Hopkins, Imperial College London, and NYU — have shown that one or two doses of psilocybin, combined with psychotherapy, can produce significant reductions in depression and anxiety that persist for 6 to 12 months. The Yale spine density research gives us a plausible biological explanation for why.

The 2025 Follow-Up: Psilocybin Rewires Entire Brain Networks

The Yale team didn’t stop there. In December 2025, Kwan’s lab (now at Cornell University) published a follow-up study in the journal Cell that went even deeper.

The original 2021 study showed that psilocybin grows new spines. But it left a key question unanswered: where do those new connections lead? Growing spines is great, but if they’re connecting to random neurons, that’s not necessarily therapeutic. The team needed to map which brain regions were being wired together.

To do this, they used an ingeniously modified rabies virus — engineered to jump from neuron to neuron without causing disease — as a biological GPS system to trace psilocybin’s rewiring across the entire mouse brain.

What they found was remarkable: psilocybin’s rewiring is network-specific. It doesn’t randomly grow connections everywhere. Instead, it selectively strengthens pathways from sensory and medial brain regions (the mouse equivalent of the human default mode network) to subcortical targets involved in action and emotion. At the same time, it weakens cortico-cortical feedback loops — the recurrent neural circuits associated with rumination and repetitive negative thinking.

In plain language: psilocybin breaks the mental loops that keep you stuck in depressive thought patterns while simultaneously building stronger connections between perception, emotion, and action.

As Kwan explained: “Rumination is one of the main points for depression, where people have this unhealthy focus and they keep dwelling on the same negative thoughts. By reducing some of these feedback loops, our findings are consistent with the interpretation that psilocybin may rewire the brain to break, or at least weaken, that cycle.”

This study also confirmed something important: the rewiring is activity-dependent. That means the new connections aren’t random — they’re shaped by the neural activity that occurs during the psilocybin experience itself. The trip matters. The thoughts, emotions, and insights you have during your journey are literally sculpting your brain’s new architecture in real time.

How Psilocybin Triggers Neuroplasticity: The Molecular Pathway

So how does a single molecule trigger all of this structural change? Let’s trace the pathway.

Step 1: Psilocin Activates Serotonin 2A Receptors

When you consume magic mushrooms, your body converts psilocybin into psilocin. Psilocin binds to serotonin 2A receptors (5-HT2A), which are densely concentrated on the apical dendrites of pyramidal neurons in the prefrontal cortex — the exact cells where spine growth occurs. A 2025 study published in Nature by Kwan’s team confirmed that psilocybin’s lasting structural effects specifically require 5-HT2A receptors and particular pyramidal cell types.

Step 2: BDNF and mTOR Pathways Are Activated

When those receptors are stimulated, they trigger a cascade of intracellular signaling pathways. The two most important are:

BDNF (Brain-Derived Neurotrophic Factor): Often called “fertilizer for the brain,” BDNF is a protein that promotes the survival, growth, and differentiation of neurons. Psilocybin has been shown to increase BDNF expression. A 2023 study published in Nature Neuroscience found that psychedelics promote plasticity by directly binding to the BDNF receptor TrkB — suggesting a mechanism independent of, or complementary to, 5-HT2A activation.

mTOR (mammalian Target of Rapamycin): This signaling pathway regulates cell growth and protein synthesis. When activated, it promotes the formation of new dendritic spines and synaptic connections. Psilocybin activates mTOR in the prefrontal cortex, directly driving spine growth.

Step 3: New Spines Form and Mature

Within hours of psilocybin administration, new dendritic spines begin to appear. These nascent spines take about 4 days to mature into functional synapses. The Yale study showed that a fraction of these psilocybin-induced spines remained stable for at least a month, suggesting they’ve been fully integrated into the brain’s circuitry.

Step 4: Excitatory Neurotransmission Increases

The new spines aren’t just structural — they’re functional. The Yale team measured increases in miniature excitatory postsynaptic currents (mEPSCs), confirming that the newly grown connections are actively transmitting signals. The brain isn’t just growing new hardware; it’s turning it on.

What About Microdosing?

Most of the spine density research has been conducted with full psychedelic doses. But what about microdosing?

The honest answer: we don’t know for certain yet. There are far fewer studies on microdose-level neuroplasticity. But there’s reason to be optimistic.

A 2024 study published in the Journal of Psychopharmacology found that psilocybin promotes neuroplasticity and produces antidepressant-like effects in mice at varying doses. Preclinical evidence from the OPEN Foundation’s systematic review shows that neuroplastic effects — including elevated BDNF, spine density changes, and neurogenesis markers — appear in a dose-dependent manner, with even lower doses producing measurable effects in some studies.

There’s also the indirect evidence from the Stamets Protocol (psilocybin stacked with Lion’s Mane and Niacin), which Paul Stamets theorizes could amplify neuroplastic effects at sub-perceptual doses. Lion’s Mane independently stimulates Nerve Growth Factor (NGF), potentially complementing psilocybin’s effects on BDNF and spine growth. If you’re curious about microdose capsules that use these kinds of blends, check out our Microdose Capsules: Benefits, Blends, and What to Expect.

The bottom line: full doses have the strongest evidence for structural neuroplasticity. But microdosing likely contributes to neuroplastic change too — we just need more studies to confirm the dose-response relationship.

Psilocybin vs. Traditional Antidepressants: A Different Approach to the Same Problem

Traditional SSRIs (like Zoloft, Prozac, and Lexapro) increase serotonin availability in the brain. They can be effective for many people, but they come with significant limitations:

• They take 4–6 weeks to produce noticeable effects
• They must be taken daily, often for years or indefinitely
• They come with side effects like weight gain, sexual dysfunction, and emotional blunting
• They don’t appear to directly rebuild lost neural connections
• Stopping them can cause withdrawal symptoms

Psilocybin works through a fundamentally different mechanism. Rather than chronically modulating serotonin levels, it produces an acute burst of 5-HT2A activation that triggers a cascade of structural changes — new spines, new connections, new pathways — that persist long after the compound has left the body.

It’s the difference between taking a daily supplement to manage a deficiency versus doing a single intensive treatment that repairs the underlying damage.

That said, psilocybin isn’t a replacement for SSRIs for everyone. It’s not FDA-approved for depression (yet). It requires careful preparation, the right setting, and ideally professional guidance. And it’s not appropriate for people with certain conditions like schizophrenia or a family history of psychosis. But the neuroplasticity research makes a compelling case that psilocybin addresses depression at a deeper, structural level than most current treatments.

The Bigger Picture: Neuroplasticity Beyond Depression

While depression has been the primary focus of psilocybin neuroplasticity research, the implications extend far beyond mood disorders.

PTSD: Fear-based disorders involve rigid neural circuits that lock people into trauma responses. Research from Kwan’s lab has shown that psilocybin facilitates fear extinction in mice — the process of unlearning fear responses — through neuroplastic mechanisms. This has obvious implications for PTSD treatment.

Addiction: Substance use disorders are associated with reduced prefrontal cortex function and weakened executive control circuits. By rebuilding connections in these areas, psilocybin could help restore the brain’s ability to regulate impulses and make healthier decisions. Early clinical trials at Johns Hopkins have shown promising results for psilocybin-assisted therapy in treating alcohol and tobacco addiction.

Neurodegenerative Diseases: A groundbreaking pilot study from UCSF tested psilocybin on Parkinson’s disease patients and found improvements not just in mood, but in cognition and motor function. The researchers suggested psilocybin may help the brain repair itself by reducing neuroinflammation and promoting neuroplasticity — the same spine-growing mechanism documented at Yale.

Cognitive Flexibility: Even in healthy individuals, psilocybin’s neuroplastic effects may enhance creative thinking, problem-solving, and the ability to break out of rigid thought patterns. This is likely part of why microdosing has become so popular among creatives and professionals.

What This Means for You

If you’re reading this and thinking, “Okay, so psilocybin literally grows new brain connections. What do I do with that information?” — here are some practical takeaways:

1. The Trip Is Part of the Medicine

The 2025 Cell study confirmed that psilocybin’s rewiring is activity-dependent. The neural activity during your experience shapes which connections are built. This means set and setting aren’t just nice-to-haves — they’re biologically important. Go in with intention. Create a safe, comfortable environment. The quality of your experience directly influences the quality of your brain’s restructuring. Our 10 Best Activities on Magic Mushrooms blog can help you plan.

2. Integration Matters More Than You Think

New spines take about 4 days to mature into functional synapses. The weeks following a psilocybin experience are a critical window where your brain is consolidating new connections. This is why integration — journaling, therapy, reflection, and mindful lifestyle choices — is so important. You’re not just processing the experience emotionally; you’re supporting the biological maturation of new neural pathways.

3. Spacing Your Sessions Is Smart Biology

Your brain needs time to build and stabilize new connections. Rushing back for another trip before the previous round of neuroplasticity has matured is counterproductive. The standard recommendation of waiting at least 14 days between sessions isn’t just about tolerance — it’s about giving your brain time to finish its construction project. For more on this, read our full guide on Psilocybin Tolerance.

4. Support Your Brain’s Building Materials

Neuroplasticity requires raw materials: protein, omega-3 fatty acids, B vitamins, adequate sleep, and regular exercise. If you’re interested in maximizing the neuroplastic potential of psilocybin, support your brain with good nutrition, quality rest, and physical activity before and after your experience. Think of it like providing building materials for a construction crew that’s about to get to work.

5. Choose Your Strain Wisely

Different strains produce different intensities of experience, which likely correlates with different levels of receptor activation and neuroplastic stimulation. If you’re specifically interested in the therapeutic and neuroplastic potential, a moderate-to-strong experience with a well-characterized strain is likely more effective than a barely-perceptible microdose. Our guide on How Different Strains Affect Your Experience can help you choose.

Frequently Asked Questions

Does psilocybin actually grow new brain cells?

The Yale research focused on dendritic spines — new connections between existing neurons — rather than entirely new brain cells (neurogenesis). However, other studies have shown that psilocybin can promote neurogenesis in the hippocampus (the growth of brand new neurons), particularly at low to moderate doses. So the answer is: it does both — grows new connections and potentially new cells.

How long do the new connections last?

The Yale study tracked spines for 34 days and found that a significant portion of the new connections were still present. The 2025 Cell study confirmed that the network-level rewiring is also persistent. The exact upper limit isn’t known, but the structural changes appear to last at least several weeks to months.

Do I need a “heroic dose” for neuroplasticity?

Not necessarily. The Yale mouse study used a dose equivalent to a moderate human experience. The neuroplastic effects appear to be dose-dependent, meaning more intense experiences may produce more structural change. But even moderate doses produced significant spine growth. The key is having a meaningful experience, not an overwhelming one.

Can I see these changes on a brain scan?

A 2024 study published in Nature used precision functional mapping (fMRI) in humans and confirmed that a single dose of psilocybin produces detectable changes in brain connectivity that persist for weeks after the experience. So while we can’t see individual dendritic spines in living humans, we can see the larger-scale connectivity changes that result from them.

Is this why psilocybin helps with depression when SSRIs don’t?

Possibly. SSRIs work by increasing serotonin availability but don’t directly promote spine growth. Psilocybin activates the same receptor system but through a different mechanism — an acute burst of 5-HT2A activation that triggers structural remodeling. For people with treatment-resistant depression, this structural approach may address the root cause (lost connections) rather than just managing the symptoms.

The Bottom Line

The science is clear and getting clearer every year: psilocybin doesn’t just change how you feel during a trip. It physically changes the structure of your brain — growing new connections, strengthening communication between neurons, and selectively rewiring neural networks in ways that break the patterns underlying depression, anxiety, and rigid thinking.

From the landmark 2021 Yale study showing a 10% increase in dendritic spine density from a single dose, to the 2025 Cell paper mapping exactly how psilocybin rewires entire brain networks, the evidence paints a consistent picture: this compound promotes rapid, lasting structural change in the brain regions most affected by mental illness.

We’re still in the early chapters of understanding psilocybin’s full neuroplastic potential. But what we know so far is extraordinary — and it explains why so many people describe their mushroom experiences as genuinely life-changing.

Because at a biological level, they are.

Happy tripping!

Curious to explore the neuroplastic potential of psilocybin for yourself? Browse our full selection of magic mushrooms, or start with our microdose capsules for a gentler introduction.

Sources

1. Shao et al. (2021) — “Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo” — Neuron — https://pubmed.ncbi.nlm.nih.gov/34228959/
2. Yale News (2021) — “Psychedelic spurs growth of neural connections lost in depression” — https://news.yale.edu/2021/07/05/psychedelic-spurs-growth-neural-connections-lost-depression
3. Jiang et al. (2025) — “Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks” — Cell — https://www.cell.com/cell/fulltext/S0092-8674(25)01305-4
4. Cornell Chronicle (2025) — “A dose of psilocybin, a dash of rabies point to treatment for depression” — https://news.cornell.edu/stories/2025/12/dose-psilocybin-dash-rabies-point-treatment-depression
5. Shao et al. (2025) — “Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors” — Nature — https://pubmed.ncbi.nlm.nih.gov/40175553/
6. OPEN Foundation (2025) — “Psilocybin and Neuroplasticity: A Review of Preclinical and Clinical Studies” — https://open-foundation.org/psilocybin-and-neuroplasticity/
7. Siegel et al. (2024) — “Psilocybin desynchronizes the human brain” — Nature — https://www.nature.com/articles/s41586-024-07624-5
8. UCSF (2025) — “How Magic Mushrooms Could Help Parkinson’s Disease Patients” — https://www.ucsf.edu/news/2025/04/429906/how-magic-mushrooms-could-help-parkinsons-disease-patients
9. Health Canada — Psilocybin and Psilocin (Magic Mushrooms) — https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html
10. Johns Hopkins Center for Psychedelic & Consciousness Research — https://www.hopkinspsychedelic.org/

Disclaimer: This blog is for educational and harm reduction purposes only and is not medical advice.

Let’s talk about something heavy — but important.

Post-traumatic stress disorder affects millions of people worldwide. Veterans, first responders, survivors of abuse, accident victims, anyone who’s lived through something their brain couldn’t fully process at the time. The flashbacks. The hypervigilance. The emotional numbness. The nightmares that make sleep feel like enemy territory.

For decades, PTSD treatment has relied on a fairly narrow toolkit — SSRIs, talk therapy, exposure therapy, and a lot of “give it time.” And while those approaches help some people, the reality is that a staggering number of PTSD sufferers don’t get better. They try treatment after treatment, and the trauma stays locked in place.

That’s why the emerging research on psilocybin for PTSD is generating so much excitement — and so much hope. Early clinical trials are showing that psilocybin-assisted therapy may offer something the current system can’t: rapid, lasting relief from symptoms that have resisted everything else.

This isn’t hype. This is science. And it’s moving fast.

What Is PTSD, Really?

Before we get into how psilocybin might help, let’s make sure we’re on the same page about what PTSD actually is — because it’s widely misunderstood.

PTSD isn’t just “being stressed” or “having bad memories.” It’s a clinical condition where the brain essentially gets stuck in survival mode after a traumatic event. The threat is long gone, but the nervous system hasn’t gotten the memo. It keeps firing as if the danger is still present — every day, sometimes for years or decades.

Common PTSD symptoms include:

• Re-experiencing: Flashbacks, intrusive memories, nightmares that feel like you’re reliving the event
• Avoidance: Steering clear of people, places, or situations that remind you of the trauma
• Hyperarousal: Being constantly on edge, irritable, easily startled, unable to sleep
• Negative changes in mood and thinking: Emotional numbness, guilt, shame, feeling disconnected from others, loss of interest in things you used to enjoy

Here’s a number that puts the problem in perspective: approximately 13 million Americans are living with PTSD at any given time, and only two pharmacological treatments have been approved in the last two decades. Both are SSRIs (sertraline and paroxetine), and their effectiveness — particularly for veterans — leaves a lot to be desired.

The need for something new isn’t just real. It’s urgent.

Why Current PTSD Treatments Fall Short

Let’s be blunt about the current landscape.

SSRIs: The Default Prescription

SSRIs (Selective Serotonin Reuptake Inhibitors) are the most commonly prescribed medications for PTSD. They work by increasing serotonin levels in the brain, which can help regulate mood. But here’s the problem: for many people with PTSD — especially veterans — they simply don’t work well enough.

Response rates are modest. Side effects (weight gain, sexual dysfunction, emotional blunting) are common. And they need to be taken daily, often indefinitely. For a condition rooted in deep psychological trauma, a pill that tweaks your brain chemistry by a few percentage points often isn’t enough to break the cycle.

Psychotherapy: Effective but Incomplete

Evidence-based therapies like Cognitive Processing Therapy (CPT), Prolonged Exposure (PE), and EMDR can be genuinely helpful. But they have significant limitations:

• High dropout rates. PTSD therapy is hard. It requires you to deliberately engage with your worst memories, and many people can’t sustain that over weeks or months of sessions.
• Limited access. Qualified trauma therapists are in short supply, wait times are long, and cost is a barrier for many.
• Non-response. A substantial percentage of people complete the full course of therapy and still meet diagnostic criteria for PTSD afterward.

The result? Millions of people stuck in a loop — cycling through treatments that don’t fully work, often losing hope along the way.

Enter Psilocybin: A Different Approach to Trauma

Psilocybin isn’t a new discovery. Indigenous cultures have used psilocybin-containing mushrooms for thousands of years in healing and spiritual ceremonies. But in the context of modern psychiatric research, psilocybin represents something genuinely novel — a treatment that doesn’t just manage symptoms, but may actually help the brain process and release the underlying trauma.

Here’s the key distinction: most PTSD medications work by dampening symptoms. Psilocybin appears to work by temporarily opening a window of psychological flexibility — a state where the brain can revisit traumatic material without the usual overwhelming fear response, process it differently, and form new, healthier neural pathways around it.

It’s not about numbing the pain. It’s about finally being able to move through it.

How Psilocybin Works in the Brain

To understand why psilocybin might be uniquely suited for PTSD, we need to look at what it does at the neurological level.

The Default Mode Network

Your brain has a network of interconnected regions called the Default Mode Network (DMN). The DMN is most active when you’re engaged in self-referential thinking — ruminating about the past, worrying about the future, constructing your sense of identity, running the same mental loops over and over.

In people with PTSD, the DMN is often overactive. It’s like a broken record player stuck on the worst tracks. The same traumatic memories, the same fear responses, the same rigid thought patterns — playing on repeat, day after day.

Psilocybin temporarily quiets the DMN. It doesn’t shut it off — it loosens its grip. This creates a state where rigid mental patterns become flexible, and the brain can form new connections that weren’t available before. Researchers describe it as a “reset” — a temporary window where entrenched neural pathways can be restructured.

Fear Extinction

One of the most exciting findings in recent preclinical research is that psilocybin appears to enhance fear extinction — the process by which the brain learns that a previously threatening stimulus is no longer dangerous. This is essentially what exposure therapy tries to accomplish, but psilocybin may supercharge the process.

A 2024 study published in ACS Chemical Neuroscience found that psilocybin enhanced fear extinction in animal models, with effects that lasted well beyond the dosing period. Importantly, the effect was most pronounced when psilocybin was administered alongside extinction exposure — suggesting that combining psilocybin with therapy may be the key to unlocking its full potential for PTSD.

Neuroplasticity

Psilocybin also promotes neuroplasticity — the brain’s ability to form new neural connections. Trauma essentially carves deep grooves in the brain’s wiring, making certain fear-based pathways automatic and hard to override. Psilocybin may help by encouraging the growth of new connections (particularly in the prefrontal cortex) that can compete with and eventually replace those trauma-driven pathways.

Research from Yale has shown that a single dose of psilocybin can increase dendritic spine density — the tiny protrusions on brain cells that receive signals from other neurons — and that these changes can persist for at least a month. For someone whose brain has been stuck in survival mode for years, this kind of structural rewiring could be transformative.

Emotional Processing Without the Panic

Perhaps the most relevant effect for PTSD: psilocybin reduces activity in the amygdala, the brain’s fear-processing centre. Under normal PTSD conditions, the amygdala hijacks the response to any trauma-related trigger, flooding the system with fight-or-flight hormones. It’s what makes a car backfiring feel like a mortar round, or a crowded room feel like an ambush.

With psilocybin, people report being able to access traumatic memories without the usual overwhelming emotional reaction. The memory is still there, but the terror is softened. This creates an opportunity to process the event from a new perspective — often with a therapist guiding the experience — and to integrate it into your life story in a way that doesn’t keep re-traumatizing you.

What the Research Says: Clinical Trials and Key Studies

The clinical evidence for psilocybin and PTSD is still early-stage compared to depression research, but it’s building rapidly — and the results so far are genuinely encouraging.

Compass Pathways: COMP360 Phase 2 Trial

One of the most significant studies to date comes from Compass Pathways, a biotechnology company developing psilocybin-based treatments. Their Phase 2 trial evaluated a single 25 mg dose of synthetic psilocybin (COMP360) in 22 patients with PTSD. The results, published in the Journal of Psychopharmacology in 2025, showed that COMP360 was well tolerated with no serious adverse events, and patients showed both rapid and durable improvement in PTSD symptoms out to 12 weeks after a single dose.

The FDA has since accepted Compass Pathways’ Investigational New Drug application to proceed with larger clinical trials of COMP360 for PTSD — a major step toward potential approval.

VA Palo Alto: Veterans with Treatment-Resistant Depression and PTSD

A landmark pilot study at the Veterans Affairs Palo Alto Healthcare System gave 25 mg of psilocybin to 15 veterans with severe treatment-resistant depression — many of whom also had comorbid PTSD. At three weeks, 60% of participants met response criteria and 53% achieved remission. At 12 weeks, 47% still showed a response and 40% remained in remission. Long-term follow-up data through 12 months continued to show sustained benefits.

Notably, comorbid PTSD did not negatively impact the treatment outcomes — suggesting that psilocybin may be effective even in people carrying both conditions simultaneously.

The VA Begins Funding Psychedelic Research

In a historic move, the U.S. Department of Veterans Affairs issued a request for research proposals to study psilocybin and MDMA for treating PTSD and depression in veterans. This was the first time since the 1960s that the VA funded research into psychedelic compounds — a massive signal that the institutional tide is turning.

Psychedelic Retreats for Veterans

Outside of formal clinical trials, observational research on veterans attending psychedelic retreats has also shown promising results. A 2025 study published in PMC found significant improvements across eight mental health outcomes following psychedelic retreats, with the greatest improvements found for depression (29.1%) and PTSD (26.1%). Veterans attending psilocybin retreats showed improvements in seven out of eight outcomes measured.

How Psilocybin-Assisted Therapy Actually Works

It’s crucial to understand: we’re not talking about someone eating mushrooms alone in their bedroom and hoping for the best. Psilocybin-assisted therapy is a structured, multi-phase clinical process.

Phase 1: Preparation Sessions

Before any psilocybin is administered, patients go through multiple preparation sessions with trained therapists. These sessions build rapport, establish trust, set intentions for the experience, and prepare the patient for what they might encounter during the psilocybin session — including the possibility of confronting difficult emotions or traumatic memories.

This phase is especially important for PTSD patients, who may have deep-seated mistrust of authority figures and institutions. Creating a sense of safety is foundational.

Phase 2: The Psilocybin Session

The actual dosing session takes place in a comfortable, controlled clinical environment — nothing like a hospital room. Think soft lighting, comfortable furniture, curated music playlists, and two trained therapists present at all times.

The patient takes the psilocybin dose (typically 25 mg in clinical trials) and lies down, often with an eye mask and headphones. The therapists don’t direct the experience — they provide a safe container for whatever arises. Sometimes that’s profound emotional release. Sometimes it’s vivid imagery related to the trauma. Sometimes it’s a deep sense of peace and interconnection. The experience typically lasts 6–8 hours.

Phase 3: Integration Sessions

This is arguably the most important phase. In the days and weeks following the psilocybin session, patients work with their therapists to make sense of what they experienced — to integrate the insights, emotions, and perspectives into their daily life.

Without integration, the psilocybin experience can remain a powerful but isolated event. With it, the insights from the session become lasting changes in how the person relates to their trauma, their identity, and their future.

Psilocybin vs. MDMA for PTSD

You might be wondering: what about MDMA? It’s been in the PTSD headlines even more than psilocybin.

MDMA-assisted therapy and psilocybin-assisted therapy both show tremendous promise for PTSD, but they work differently and may serve different needs.

MDMA primarily works by increasing feelings of empathy, trust, and emotional safety. It allows people to revisit traumatic memories without the usual fear response, making it an ideal companion for talk-based therapy. MDMA-assisted therapy has shown 71% long-term PTSD relief rates in clinical trials — genuinely remarkable numbers.

Psilocybin works differently. It disrupts rigid brain patterns, enhances neuroplasticity, and can trigger profound mystical or self-transcendent experiences that fundamentally shift perspective. It’s less about opening up emotionally in a therapy session and more about restructuring the brain’s relationship with trauma at a deep, sometimes pre-verbal level.

The FDA rejected MDMA therapy in 2024, asking for additional data. That setback has actually accelerated interest in psilocybin as an alternative pathway — and Compass Pathways is now actively pursuing psilocybin specifically for PTSD through advanced clinical trials.

It’s possible the future will involve both substances being available for different types of trauma, different patient profiles, and different stages of recovery. They’re not competitors — they’re complementary tools.

Can You Self-Treat PTSD with Psilocybin?

This is the elephant in the room, so let’s address it directly.

Many people with PTSD — especially veterans who’ve exhausted their options within the VA system — are turning to psilocybin on their own. Some travel to retreats in Jamaica, Costa Rica, or the Netherlands. Others access mushrooms through grey markets or grow their own. And some are finding genuine relief.

But we need to be honest about the risks:

PTSD makes psychedelic experiences unpredictable. Trauma can surface during a psilocybin session in ways that are overwhelming, disorienting, or re-traumatizing — especially without a trained professional present. The very thing that makes psilocybin potentially healing (its ability to unlock repressed material) is also what makes it potentially harmful if the experience isn’t properly supported.

Set and setting matter enormously. The research consistently shows that the therapeutic benefits of psilocybin are strongly tied to the preparation, environment, and integration support surrounding the experience. A solo trip in your apartment is a fundamentally different thing from a professionally guided session.

Dosing matters. Too little might not be therapeutic. Too much can be destabilizing. And the potency of different mushroom strains varies significantly — something we cover in detail in our guide on How Different Strains Affect Your Experience.

We’re not going to tell you what to do. But we will say this: if you’re dealing with PTSD and considering psilocybin, please do your homework. Learn about how mushrooms actually make you feel. Consider whether microdosing — a much gentler starting point — might be a better first step. And if possible, work with someone experienced.

Microdosing for PTSD: A Gentler Path

Not everyone is ready for a full psychedelic experience — and that’s completely valid.

Microdosing (taking sub-perceptual doses of psilocybin, typically 0.1–0.3g) is increasingly being explored by people with PTSD as a way to gently shift their neurochemistry without the intensity of a full trip. The experience is subtle — no hallucinations, no altered reality — just a quiet lift in mood, a softening of emotional reactivity, and often a sense that the world feels slightly less threatening.

Survey data supports what many microdosers report anecdotally: people who microdose tend to report lower levels of depression, anxiety, and stress compared to non-microdosers. While we don’t yet have clinical trials specifically testing microdosing for PTSD, the overlap between PTSD symptoms and the conditions microdosing appears to improve (anxiety, depression, emotional rigidity) is compelling.

If you’re curious about this approach, our Microdosing 101 guide covers everything from protocols to common mistakes. And our blog on The Science of How Microdosing Helps with Depression and Anxiety goes deeper into the mechanisms.

The Road Ahead: What’s Coming Next

The psilocybin-for-PTSD research pipeline is fuller than it’s ever been:

• Compass Pathways is advancing COMP360 into late-stage clinical trials specifically for PTSD, with FDA acceptance of their Investigational New Drug application.
• The VA is funding multiple studies on psilocybin and MDMA for veteran populations — a historic shift in institutional policy.
• Johns Hopkins has listed PTSD among the conditions it’s actively studying in its Center for Psychedelic and Consciousness Research.
• Ohio State University has an ongoing open-label pilot study combining psilocybin-assisted therapy with psychotherapy specifically for veterans with severe, treatment-resistant PTSD.
• University of Washington is enrolling veterans and first responders with co-occurring alcohol use disorder and PTSD for a psilocybin treatment study.

We’re still in the early chapters of this story. Psilocybin hasn’t been FDA-approved for PTSD yet, and it may be years before it is — if the clinical trials continue to show positive results. But the trajectory is unmistakable, and the need is too great to ignore.

Frequently Asked Questions

Is psilocybin FDA-approved for PTSD?

Not yet. Psilocybin is still a Schedule I substance in the United States and remains controlled in Canada under the CDSA. However, the FDA has granted breakthrough therapy designation to psilocybin for treatment-resistant depression, and clinical trials for PTSD are now underway. In Canada, limited access exists through Health Canada’s Special Access Program.

How is psilocybin therapy different from just taking mushrooms?

Psilocybin-assisted therapy involves structured preparation sessions, a professionally supervised dosing session in a therapeutic environment, and follow-up integration sessions with trained therapists. It’s a complete therapeutic framework — not just a drug. The therapy component appears to be a critical part of why it works.

Can psilocybin make PTSD worse?

It’s possible. Psilocybin can bring suppressed traumatic material to the surface in ways that feel overwhelming, especially without proper support. People with dissociative symptoms, active psychosis, or certain personality disorders face additional risks. This is why clinical trials use extensive screening and always have trained therapists present.

What about microdosing for PTSD?

Microdosing is a much lower-risk approach that some people with PTSD are exploring. It doesn’t produce the dramatic breakthroughs seen in full-dose therapy sessions, but many users report gradual improvements in mood, emotional regulation, and stress response over time. Check out our microdose capsules guide if you’re interested.

Is psilocybin legal in Canada for PTSD treatment?

Psilocybin is classified as a controlled substance under Canada’s Controlled Drugs and Substances Act. However, healthcare professionals can request access on behalf of patients through Health Canada’s Special Access Program, and individual exemptions can be granted. Our blog on The Legal Status of Magic Mushrooms in Canada has more detail.

How long do the effects of psilocybin therapy last?

Clinical trials have shown symptom improvement lasting anywhere from several weeks to 12 months or more after a single dose. This durability is one of the most remarkable aspects of psilocybin therapy — a single session producing effects that outlast months of daily medication.

The Bottom Line

PTSD is a condition that locks people in their past. The trauma becomes a prison — one that’s invisible to everyone else but inescapable for the person living inside it.

What makes psilocybin so promising isn’t just that it reduces symptoms. It’s that it appears to help the brain actually process the trauma — to loosen the rigid neural patterns that keep people stuck, to open a window of flexibility where healing can happen, and to do all of this in a way that feels profoundly meaningful to the people going through it.

We’re not there yet. The research is still early. The legal barriers are still high. And self-treatment carries real risks that shouldn’t be minimized.

But the direction is clear. And for millions of people living with trauma that hasn’t responded to anything else, that direction is hope.

If you want to learn more about how psilocybin affects the brain and body, start with our guide on How Shrooms Make You Feel. If you’re exploring microdosing as a starting point, browse our full product selection or check out our microdose capsules.

Stay informed. Stay safe. And stay hopeful.

Sources

1. Compass Pathways — Phase 2 Study of COMP360 Psilocybin for PTSD (2025) — Compass Pathways Press Release
2. U.S. Department of Veterans Affairs — Psychedelic-Assisted Therapy for PTSD — https://www.ptsd.va.gov
3. VA News — VA to Fund Studies on Psychedelic Therapies for PTSD — https://news.va.gov
4. Johns Hopkins Center for Psychedelic and Consciousness Research — https://www.hopkinsmedicine.org
5. Journal of Psychopharmacology — McGowan et al. (2025), Safety and Tolerability of Psilocybin for PTSD — https://journals.sagepub.com
6. CPR News — Can Psilocybin Help Veterans with PTSD? (2025) — https://www.cpr.org
7. PMC — Exploring Therapeutic Effects of Psychedelics in Military Veterans (2025) — https://pmc.ncbi.nlm.nih.gov
8. GlobalRPH — Psychedelic Therapy in 2025: Clinical Outcomes — https://globalrph.com

Disclaimer: This blog is for educational and harm reduction purposes only and is not medical advice. If you are experiencing PTSD symptoms, please consult a qualified healthcare professional. Magic mushrooms are classified as controlled substances in most jurisdictions. Always research the laws in your area before considering any psychedelic substance.